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II.
ABSTRACT
Medulloblastoma is the most common malignant childhood brain tumour, and the most
significant cause of childhood cancer-related mortality. Recently four core molecular
medulloblastoma sub-groups have been identified, with distinct pathogenesis and responses
to therapies. Current therapies, do not account for this molecular variation, and many patients
may receive inappropriate treatment. To address this, targeted therapies for each molecular
sub-group would be ideal. Unfortunately, for the more aggressive Group 3 and Group 4 subgroups, the underlying mechanisms of pathogenesis remain poorly understood. The current
challenge is to identify the key tumour suppressors or oncogenes involved in Group 3 and
Group 4 pathogenesis, which may ultimately lead to the development of new therapeutic
targets.

Transcriptional profiling studies of medulloblastoma have identified numerous genes
commonly affected in other cancers, which may also contribute to medulloblastoma
pathogenesis. One potential candidate is Dachshund Homolog 1 (DACH1), which has upregulated expression across all medulloblastoma sub-groups, relative to normal cerebellum,
consistent with a potential oncogenic role. This up-regulation is most significant in the Group
4 tumours and is consistent with recent methylation profiling analyses, correlating increased
DACH1 expression with gene hypomethylation. This combined evidence suggests that
DACH1 may be a medulloblastoma oncogene. Oncogenic over-expression of DACH1 has
been demonstrated in both ovarian and colorectal cancers, and is associated with cancer
progression and invasiveness, but has not previously been linked to medulloblastoma
pathogenesis. Additionally the mechanisms associated with over-expression of DACH1 have
not been explored in any cancers; however epigenetic modulation is likely, as DACH1
mutations are relatively rare in most cancer types, and DACH1 mutations in medulloblastoma
have not been identified.

Deregulated expression of numerous microRNAs has been identified in various cancers,
including medulloblastoma, demonstrating the role of microRNAs in cancer initiation and
progression. MicroRNAs provide a potential epigenetic mechanism for regulation of
1

DACH1. Analysis of the DACH1 3’UTR using TargetScan revealed a potential binding sites
for nine individual/clusters of miRNAs (Figure 10). One putative miRNA is miR-200b,
belonging to the highly conserved microRNA-200 family (miR-200). miR-200 is frequently
down-regulated in metastatic cancers, raising the possibility that the miR-200 family may
play a role in the pathogenesis of metastatic Group 4 medulloblastoma.

There is an apparent association between high levels of DACH1 expression and low level of
miR-200b, and in silico analysis using TargetScan identified a putative binding site for miR200b within the DACH1 3’-UTR at nucleotides 971-978. Previous evidence supports the role
of both DACH1 and miR-200b in metastatic progression; however an association between the
two has not previously been described. Here we propose that deregulated DACH1 was
associated with loss of regulation by miR-200b, and demonstrated an inverse correlation
between DACH1 and mir-200b expression in representative medulloblastoma cell lines,
which was further assessed.
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1.0

MEDULLOBLASTOMA

Medulloblastoma is the most common malignant brain tumour in children, and occurs in the
cerebellum. The clinical heterogeneity of these tumours has now been linked to variations at
a molecular level, distinguishing at least four distinct sub-groups. These core sub-groups
include the Sonic Hedgehog tumours (SHH), Wingless tumours (WNT), Group 3 tumours,
and Group 4 tumours. For SHH and WNT tumours, aberrant overexpression of the respective
pathways is responsible for driving tumourigenesis. However, the pathogenesis of both
Group 3 and Group 4 tumours is more complex, most likely involving interactions between
different signalling and genetic factors. In Group 3, MYC amplification is the most striking
abnormality, and in Group 4, recurrent mutations affecting epigenetic regulator genes are
prominent.

Given the molecular and clinical heterogeneity of medulloblastoma, it would be ideal to treat
patients according to molecular sub-group, however current treatment regimens are
determined using a risk stratification that classifies patients as either high risk or low risk high risk being those aged ≥ 3 years at diagnosis, with metastatic dissemination and/or ≥
1.5cm2 residual tumour following surgical resection, or < 3 years of age at diagnosis, and
those of average risk being ≥ 3 years of age at diagnosis, without metastatic dissemination,
and ≤1.5cm2 residual tumour following surgical resection (DeSouza, Jones, Lowis, & Kurian,
2014; Klesse & Bowers, 2010; Pizer & Clifford, 2008). Patients receive a combination of
therapies, depending on ‘risk’, including surgical resection, craniospinal radiation, and a
combination of chemotherapeutic agents (Wlodarski & Jozwiak, 2008). While the use of
combination therapy has greatly improved patient survival, serious long-term post-treatment
related health issues are common due to the aggressive nature of treatment. Given the current
risk-based approach (for determining treatment) does not account for the molecular
heterogeneity and the variability in outcome associated with each sub-group, some patients
may receive inadequate treatment, while others receive unnecessarily aggressive treatment.
This highlights the importance of a therapeutic approach based on molecular sub-group and
patient prognosis (Northcott et al., 2011), and the need to develop therapies that are subgroup specific.
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SHH and WNT pathway inhibitors have been developed and some are currently utilised in
the clinic for cancer treatment. Such targeted therapies would be appropriate in treating
medulloblastoma, given the variation in tumour responsiveness to current therapies.
Particularly for the WNT sub-group patients, which have an excellent prognosis and are
likely to be ‘over-treated’ using current risk stratification, patients would greatly benefit from
less aggressive therapies that produce less detrimental side effects. In brain tumours, several
clinical trials of drugs targeting multiple components of the WNT signalling pathway are
currently underway (MacDonald, Aguilera, & Castellino, 2014). Additionally, the SMO
inhibitor; vismodegib (GDC-0449), is an FDA approved treatment for basal cell carcinoma
that is currently being trialled for SHH medulloblastoma (DeSouza et al., 2014; MacDonald
et al., 2014; Remke, Ramaswamy, & Taylor, 2013). The effectiveness of such therapies in
medulloblastoma would be a major step towards improving patient outcome. Unfortunately
for the more complex and aggressive Group 3 and Group 4 tumours, no such targeted
therapies exist. However, a more comprehensive understanding of the molecular pathogenesis
will likely identify new potential therapeutic targets, and enable the future development of
successful therapies that will improve medulloblastoma patient outcome.

1.1

The four core medulloblastoma sub-groups

It is important to understand the heterogeneity of medulloblastoma tumours at the clinical
level, as well as at the molecular level. An overview of clinical and molecular features of
each of the sub-groups is presented in Table 1. The recognition that distinct genetic profiles
exist amongst medulloblastoma tumours, has galvanised research in the field and
revolutionised the understanding of medulloblastoma pathogenesis, identifying at least four
core molecular sub-groups. Together, transcriptome, mutation, and cytogenetic analyses have
identified sub-group specific alterations, and presented numerous candidate tumour
suppressors and oncogenes for each sub-group that required additional analysis.

To elaborate on these sub-groups; both SHH and WNT medulloblastoma tumours are linked
to over-activation of the respective signalling pathways, with numerous mutations being
implicated in tumour development (Remke et al., 2013; Taylor et al., 2012). Both are
relatively well characterised with a clear understanding of the mechanisms involved in
tumourigenesis (for review, see (Huse & Holland, 2010). Over-activation of either of these
11

pathways is sufficient in tumour initiation, and is the result of mutations to intermediates
along the respective signalling pathways (Figure 1). Inactivation mutations to Suppressor of
Fused (SUFU) or Patched receptor (PTCH1), or activation mutations of Smoothened (SMO),
constitutively activate the sonic hedgehog signalling pathway with consequent overexpression of target oncogenes such as MYC family oncogenes (Huse & Holland, 2010;
Jones et al., 2012; Northcott, Taylor, et al., 2012). Similarly, aberrant activation of the WNT
signalling pathway leads to development of WNT tumours. Mutations to both the
Adenomatous polyposis coli (APC) and beta-catenin (CTNNB1) genes cause constitutive
activation of the WNT signalling pathway, leading to β-catenin accumulating in the nucleus
and activating target oncogenes such as MYC and Cyclin D1 (Huse & Holland, 2010;
Northcott, Taylor, et al., 2012).

Figure 1. Sonic Hedgehog (SHH) and Wingless (WNT) signalling pathways
The SHH and WNT signalling pathways, shown above, have both been implicated in
medulloblastoma pathogenesis. Mutations to key pathway intermediates are
associated with aberrant over-activation of the respective pathways, and are
associated with SHH and WNT medulloblastoma tumours. In the SHH signalling
pathway, mutations resulting in the inactivation of PTCH1 and/or SUFU, or
activation of SMO cause aberrant SHH signalling. Along the WNT pathway, loss
and gain of function mutations to APC and/or CTNNB1 (encoding β-catenin) cause
aberrant pathway signalling. Both result in over-expression of target oncogenes.
Figure adapted from (Huse & Holland, 2010) .
12

Murine models have been invaluable in understanding the biology of these medulloblastoma
tumours, and from a translational perspective, they are crucial in the development of preclinical trials that may lead to the development of much needed targeted therapies. Currently,
there are verified mouse models representing SHH, WNT, and Group 3 medulloblastoma
(Pöschl et al., 2014), but none for Group 4. There are a number of mouse models with various
alterations to the SHH pathway that have been useful in conducting pre-clinical trials for
SHH medulloblastoma (Pöschl et al., 2014). Similarly, WNT medulloblastoma, mouse
models with mutant CTNNB1 in combination with mutant TP53, have been generated to
better understand tumour biology, with potential use as models for testing new therapies for
WNT medulloblastoma (Gibson et al., 2010; Lau et al., 2012; Pöschl et al., 2014; Remke et
al., 2013). Only a single verified murine representation of Group 3 medulloblastoma exists,
with aberrant MYC expression (Swartling et al., 2010), and unfortunately no mouse model
that is representative of Group 4 medulloblastoma currently exists (Pöschl et al., 2014)
limiting the development of targeted therapies for one of the most aggressive and metastatic
sub-groups. In the future, overexpression of putative Group 4 medulloblastoma oncogenes,
such as DACH1, may be appropriate for consideration for the development of mouse models
representative of Group 4 medulloblastoma.
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Table 1. Summary of key features of the four core medulloblastoma sub-groups

Summarised from Min, Lee, Kim, and Park (2013); Northcott, Korshunov, Pfister, and Taylor
(2012); Northcott, Schumacher, et al. (2012); Northcott, Taylor, et al. (2012); Schroeder and
Gururangan (2014).
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1.2

Group 3 and Group 4 medulloblastoma

Group 3 and Group 4 medulloblastoma tumours have the highest overall prevalence, poor
prognosis, and highest frequency of metastasis (Table 1 and Figure 2). Despite their
aggressive nature and frequent occurrence, the molecular pathogenesis of these tumours is
not completely understood. There are recurrent abnormalities, including mutations to genes
that are associated with chromatin remodelling and overexpression of genes associated with
neuronal differentiation in Group 4, and retinal development in Group 3 (Taylor et al., 2012),
and frequent amplification of MYC/MYCN which is an indicator of poor prognosis
(Korshunov et al., 2012; Roussel & Robinson, 2013). There are also characteristic recurrent
chromosomal rearrangements, the most common being those that involve chromosome 17,
particularly frequent in Group 4 medulloblastoma (Northcott, Schumacher, et al., 2012).
While patients with i17q tend to have a poorer outcome, the biology behind this is not known.

Figure 2. Distribution of sub-group specific survival, occurrence, and metastasis
(a.) Patient survival across the four medulloblastoma sub-groups. Group 3 and Group
4 having the worst survival outcome, followed by SHH, and WNT. (b.)
Representation of occurrence of each sub-group, Group 4 is most frequently
diagnosed, followed by SHH and Group 3, and WNT being the least common. (c.)
Presence of metastatic disease in each of the four sub-groups. Metastasis is most
common amongst Group 3 and Group 4, and rare in SHH and WNT. (Image adapted
from Kool et.al., 2012).

What appears to be most significant in these tumours however, are alterations involving
epigenetic modifiers, MLL2 and MLL3, as well as KDM6A and KDM6B (Li, K.K-W., Lau,
15

K.M., Ng, H.K., 2013; Parsons et al., 2011; Schroeder & Gururangan, 2014) . The consistent
recurrent alterations to epigenetic modifiers are likely to have a critical role in Group 3 and
Group 4 medulloblastoma pathogenesis. Additionally, a change in expression of a number of
genes in medulloblastoma has been associated with changes in methylation patterns, pointing
to potential players in medulloblastoma pathogenesis (Hovestadt et al., 2014).

1.3

Potential mechanisms involved in Group 3 and Group 4 medulloblastoma
pathogenesis

The low frequency of recurrent mutations to common cancer-associated genes suggests an
additional level of complexity in medulloblastoma tumours, potentially involving epigenetic
regulatory mechanisms at the DNA, histone, and mRNA level (Dubuc et al., 2013; Lindsey,
Anderton, Lusher, & Clifford, 2005; Uziel et al., 2009). It is evident that alterations to
chromatin modifier genes are present in all sub-groups (for review see Jones, Northcott,
Kool, and Pfister (2013)). Most commonly identified across all sub-groups were mutations to
the methyltransferase gene MLL2, producing a truncated and non-functional protein (Parsons
et al., 2011). Sub-group specific alterations to other epigenetic modifying genes are also
observed, with both Group 3 and Group 4 showing characteristic alterations that generally
result in elevated methylation of Histone 3, lysine 27 (H3K27me3). In Group 4, there are also
recurrent mutations to the Histone 3 Lysine 27 (H3K27) histone demethylase, KDM6A,
which produce a non-functional protein (Dubuc et al., 2013). In Group 3 WNT tumours,
SMARCA4 mutations are common, while in SHH sub-group tumours, alterations to the
nuclear receptor co-repressor (N-CoR) complex are prevalent (Jones et al., 2013).

Such recurrent changes inevitably impact on the epigenetic regulation of downstream tumour
suppressor and oncogenes. In support of this, a recent analysis by Hovestadt et al. (2014)
assessed DNA methylation and gene expression levels across all medulloblastoma subgroups, and demonstrated that level of expression was correlated to methylation status of
numerous genes (Hovestadt et al., 2014). This insight provides a better understanding of the
importance of epigenetic alterations in medulloblastoma tumourigenesis.
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Additional mechanisms of genetic regulation at a post-transcriptional level have an equally
important role in regulation of gene expression. microRNAs are of note here, and will be
discussed below in section 3.0.
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2.0

DACHSHUND HOMOLOG1

The Dachshund Homolog 1 (DACH1) gene is a homolog of the Drosophila dac gene, a
regulator of cell fate determination in Drosophila eye, limb, and brain development. Dac is
an important component of the Drosophila retinal determination gene network (RDGN) for
specifying of retinal cell fate and promoting photoreceptor differentiation and programming
retinal progenitor cells (Atkins et al., 2013; Davis, Mardon, et al., 2001; Mardon, Solomon, &
Rubin, 1994). Mammalian homologues of dac -DACH1 and DACH2- show similar function
in the regulation of cell fate determination and cell proliferation, and are both important in
embryonic development, with some redundancy in their role (Davis, Shen, Sandler, Heanue,
& Mardon, 2001). In mice DACH1 is critical for post-natal survival and development and
lethal when not expressed, with homozygous DACH1 knockout mice not surviving past
postnatal day one (Davis, Mardon, et al., 2001).

In humans, the DACH1 gene, 429,233 bases long, is located on chromosome 13q22, and has
three alternative transcripts. The main DACH1 isoform is translated into a 97kDa protein
(Davis, Shen, Heanue, & Mardon, 1999). There are two functional domains, located at the Cterminus (DachBox-C) and N-terminus (DachBox-N) (Tavsanli et al., 2004), and these
binding domains enable DACH1 to modulate transcription by direct DNA binding or
interaction with other proteins, regulating cell function in a context-dependent manner
(Tavsanli et al., 2004; Zhou et al., 2010).

The context in which DACH1 is expressed varies, but the major functions include regulation
of cell proliferation and growth, and regulation of cell migration. Evidently, aberrant
expression of DACH1 has implications in the pathogenesis in several cancer types.

2.1

DACH 1 as a Tumour Suppressor

Reduced expression of DACH1 is a common feature in many cancers, and is accompanied by
changes in cell function including increased cell proliferation, migration, and tumour
progression. The tumour suppressive behaviour of DACH1 is well described in breast cancer,
where it also has clinical relevance, with reduced expression of DACH1 associated with
tumour progression and metastasis, and poor survival (Desmond et al., 2014; K. Wu et al.,
18

2006). Additional studies have led to the identification of other cancers with reduced DACH1
expression, including prostate cancer, lung cancer, and gastrointestinal cancers, as well as
others.

In breast cancer, DACH1 is linked to the regulation of cell cycling and cell proliferation by
antagonizing transcription factors such as c-Jun and FOXM1 and blocking DNA synthesis
and target gene expression associated with cell cycling (K. Wu et al., 2007; Zhou et al.,
2010). Additionally, DACH1 demonstrates anti-migratory function via inhibition of IL-8 to
repress pro-metastatic oncogenes MYC, RAS, and ErbB2 in breast cancer (Kongming. Wu et
al., 2008), and blocking YB-1 transcription factor to maintain E-cadherin expression and
epithelial phenotype (Wu et al., 2014)

Several studies have confirmed that restoring DACH1 expression results in reduced DNA
synthesis, cell proliferation, contact-independent growth, cell growth, and reduced tumour
size in cell lines and in mice (Wu et al., 2014 Wu et al., 2008, Wu et al., 2014., Yan et al.,
2014) . In addition, altered TGF-β signalling is associated with loss of DACH1, showing
increased expression in early stages of cancer, and reduced expression in advanced invasive
cancers (Wu et al., 2014, Yan et al., 2014). .

DACH1 is also involved in regulating epithelial-mesenchymal transition (EMT), and is
implicated in metastatic progression. Briefly, DACH1 repression of YB-1 inhibits induction
of transcription factors such as ‘Snail’ which regulate expression of epithelial marker Ecadherin as well as other targets (Wu, K., et al., 2014). Ultimately, repression of Snail via
YB-1 enables expression of E-cadherin and maintains a non-invasive epithelial phenotype.
DACH1 association with EMT also extends to the inhibition of TGF-β signalling, which is
lost in later stage cancers and is associated with EMT and gaining invasiveness (Yan et al.,
2014). These proposed mechanisms of DACH1 and EMT are outlined in Figure 3.
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Figure 3. Mechanisms of DACH1-mediated inhibition of EpithelialMesenchymal Transition (EMT): Expression of DACH1 inhibits TGF-β signalling
in later-stage cancers, and also represses the Y-Box1 transcription factor. These
block the expression of transcription factor Snail, an inhibitor of E-cadherin,
enabling the cell to maintain expression of the epithelial marker E-cadherin.

2.2

DACH1 as an oncogene

Consistent with the pleiotropic properties of DACH1, there are cancers that show elevated
DACH1 expression, often associated with advanced cancers with poor prognosis. Higher
levels of DACH1 are associated with cancer progression in ovarian cancer, pre-invasive
colorectal tumours (colorectal adenomas) and colorectal carcinomas, and leukaemia’s (Lee et
al., 2012; Liang et al., 2012; Vonlanthen et al., 2014).

Various studies suggest that the level of DACH1expression is associated with tumour stage
and progression, with clinical relevance for predicting patient prognosis. In ovarian cancer,
DACH1 is associated with reduced TGF-β expression, and increased cell proliferation (Sunde
et al., 2006), and also shows relevance to tumour stage, with increasing levels present as
tumours progress towards metastasis (Liang et al., 2012). Similarly, in colorectal tumours,
DACH1 is predicted to have an important role in tumourigenesis. Analysis of transcription
factor expression in colorectal adenomas and colorectal cancer indicated that DACH1 may be
important in tumour progression, with increased DACH1 in pre-invasive tumours that is
associated with highly proliferative cells (Liang Wu et al., 2014). Although the mechanisms
underlying DACH1’s role as an oncogene have not been fully explored, in hematopoietic
cells at least, elevated DACH1 has been linked to abnormalities in cell cycling and cell
differentiation (Lee et al., 2012).
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2.3

DACH1 expression in medulloblastoma

Gene expression profiling of a series of human medulloblastoma revealed that DACH1 shows
elevated expression across all medulloblastoma sub-groups compared to normal cerebellum.
DACH1 is most highly expressed in Group 4 (Figure 4.). Additionally, a recent study
investigated the level of gene expression across all medulloblastoma sub-groups, DACH1
included, according to methylation status. This showed that increased expression of DACH1
is associated with reduced methylation in medulloblastoma, and was highly associated with
Group 4 medulloblastoma (Hovestadt et al., 2014). Currently, the precise mechanisms driving
the overexpression of DACH1 in Group 4 medulloblatoma have not been investigated.
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Figure 4. DACH1 expression across all sub-groups
DACH1 expression is elevated across all four medulloblastoma sub-groups compared
to normal cerebellum, highly expressed in Group 4 medulloblastoma (Adapted from
Mark Remke, University of Toronto, Pers Comm).

2.4

Regulation of DACH1 expression

The level of DACH1 expression appears to be an important factor in cancer progression;
however the mechanisms involved have not been fully described for all cancers. Epigenetic
mechanisms have been proposed and are generally the most frequent abnormalities that
account for aberrant DACH1 expression. Promoter methylation is seen amongst several
cancers that show reduced DACH1 expression (Liang Wu et al., 2014; Yan et al., 2013; Yan
et al., 2014; H. Zhu et al., 2013), and indeed in medulloblastoma, hypomethylation of the
DACH1 gene is associated with overexpression (Hovestadt et al., 2014). Epigenetic
alterations directly affecting the DACH1 gene, combined with frequent alterations to
epigenetic modifiers in Group 3 and Group 4 medulloblastoma that may also impact DACH1
expression is consistent with a major role for epigenetic modulation of DACH1 expression in
medulloblastoma pathogenesis. One important epigenetic mechanism that may be involved in
modifying DACH1 expression is post-transcriptional regulation by microRNAs.
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3.0

MicroRNA

MicroRNAs (miRNAs) belong to a class of small non-coding RNA molecules approximately
22 nucleotides in length, and are recognised as important regulators of cell function. Their
biogenesis is outlined in Figure 5. Briefly, in the nucleus miRNAs are transcribed from the
respective miRNA gene by RNA polymerase II, into long primary microRNAs (pri-miRs).
Cleavage by the ribonucleases Drosha and Pasha (DGCR8) generates a hairpin pre-cursor
miRNAs (pre-miR) that are then exported from the nucleus. The pre-miRs are then further
processed by the ribonuclease Dicer and transactivation-responsive RNA-binding protein
(TRBP) into two short single stranded miRNAs- leading and passenger, the latter of which is
considered non-functional. Once associated with the RNA-induces silencing complex, the
‘leading’ strand guides this complex along the target mRNA where binding will initiate target
degradation or repression (see reviews Fabbri, Croce, & Calin, 2008; Finnegan & Pasquinelli,
2013).

Figure 5. The typical miRNA biogenesis pathway
miRNAs are transcribed by RNA polymerase II, and processed in the nucleus by
various ribonucleases, into premature miRNA (pre-miR). The pre-miR is transported
from the nucleus and undergoes further modification to generate two single stranded
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RNAs, one of which will interact with the RISC complex and initiate repression of
translation of target degradation (Finnegan & Pasquinelli, 2013).

3.1

microRNAs and cancer

miRNAs are capable of binding with high specificity to target mRNAs to regulate posttranscriptional gene expression. Specifically, miRNAs bind to their target via Watson-Crick
base-pairing, recognising a seed sequence within the 3’untranslated region (UTR) of a target
mRNA (Doench & Sharp, 2004). Such binding targets mRNA for degradation or by blocking
translation. This mechanism of post-transcriptional modification has provided new insight
into an additional level at which gene expression can be regulated, and has demonstrated their
importance in regulating normal cellular processes, as well as their role in tumourigenesis.
miRNAs have the capacity to function in a similar manner to tumour suppressors and
oncogenes when aberrantly expressed and are collectively referred to as oncomirs (Cho,
2007; Esquela-Kerscher & Slack, 2006). A comparison between normal and abnormal
miRNA expression is shown below in Figure 6.

So far, a number of microRNAs have been identified as key determinants in cancer, many of
which share a common role in different cancer types. For example, the over-expression of
miRNAs such as miR-155 and the miR-19~72 cluster repress tumour suppressors leading to
overexpression of oncogenes such as MYC. Others, such as miR-21 are functionally involved
in cancer progression and are also markers of poor prognosis (Cho, 2007; Huang et al., 2013;
S. Zhu et al., 2008). A more comprehensive understanding of the functional importance of
such miRNAs in cancer, will be invaluable for better understanding the role of these
molecules not only in the context of disease, but also in normal cellular physiology (Kong,
Ferland-McCollough, Jackson, & Bushell, 2012).
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Figure 6. The normal and abnormal behaviour of microRNAs
(a.) The normal function of microRNA, regulating cellular processes by bocking
translation of specific target genes. (b.) Tumour suppressive role of miRNA is lost due
to deregulated miR expression resulting in the aberrant over-expression of oncogenes.
(c.) A gain in oncogenic microRNA expression results in abnormal degradation of the
tumour suppressive targets. (Image taken from Huang et al., 2013) (DeSouza et al.,
2014) (DeSouza et al., 2014) (DeSouza et al., 2014) (DeSouza et al., 2014)

3.2

microRNA and medulloblastoma

The first study miRNA study profiling medulloblastoma tumours was conducted by Ferretti
et al. (2009), and identified a number of over- and under-expressed microRNAs in
medulloblastoma tumours and cell lines, as compared to normal cerebellum. Many
microRNAs demonstrated potential tumour suppressive activity, including miR-9 and
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miR125a. When transfected into the medulloblastoma cell line D283, both induced changes
in cell proliferation and increased cell apoptosis (Ferretti et al., 2009).

Continued efforts have identified numerous other candidate miRNAs in medulloblastoma
pathogenesis, and have focused on determining the functional significance of these miRNAs,
as well as identifying sub-group specific miRNAs that may provide prognostic markers. miR124 is a tumour suppressive miRNA in medulloblastoma, and loss of expression is associated
with uncontrolled cell proliferation as a result of increased Cyclin-Dependent Kinase 6
(CDK6) expression. Evidently, increased miR-124 is capable of silencing CDK6 expression,
and has the potential as a therapeutic to block tumour growth (Silber et al., 2013). Similarly
miR-22 is also down-regulated in medulloblastoma. Re-introducing miR-22 by transfection
increased apoptosis in-vitro, and also in-vivo, as well as reducing tumour size in xenograft
models, which was hypothesised to be, at least in part, due to targeting of the 3’phosphoadenosine 5’-phosphosulfate transporter 1 (PPAST1) gene (Xu et al., 2014).

Additionally, over-expressed miRNAs in medulloblastoma have also been identified. A study
by Genovesi, Carter, Gottardo, Giles, and Dallas (2011) compared miRNA profiles between
medulloblastoma and humans neural stem cells, a predicted cell of origin in Group 3 and
Group 4 medulloblastoma, and reported frequent up-regulation of miRNAs that are involved
in regulation of neuronal migration and signalling. Several others have an apparent role in
metastasis. For example, the miR-183~96~182 cluster is associated with the more aggressive
medulloblastoma tumours, with miR-182 in particular, being capable of inducing an
invasive/metastatic behaviour in vitro, and is associated with tumour invasion to surrounding
tissue in mouse models over-expressing miR-182 (Bai et al., 2012). A further study noted
changes in gene expression, specifically an up-regulation of transcription factors involved in
the regulation and promotion of epithelial-mesenchymal transition (EMT). This suggests that
the miR183~92~182 cluster may confer changes in invasiveness via epithelial-mesenchymal
transition (EMT) (Weeraratne et al., 2012). The EMT pathway is one which has been well
described for its role in tumour metastasis, and is discussed below.
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3.3

Epithelial-mesenchymal transition (EMT)

The metastatic process refers to a sequence of events that occur as tumour cells gain the
ability to invade surrounding tissue and disseminate within the body. These changes in cancer
cell phenotype are the result of changes in gene expression leading to loss in cell adhesion,
gaining mobility, and gaining the capacity to disseminate (Nguyen & Massagué, 2007). EMT
involves a complex network of signalling molecules, transcription factors, and microRNAs,
which regulate the transition of epithelial cells towards a mesenchymal phenotype, and the
development of features that favour metastatic dissemination. Thus aberrant activation of
EMT has been implicated as an early process in metastatic cancer (D'Amato, Howe, &
Richer, 2013).

3.3.1 microRNAs, EMT, and metastasis
There is abundant evidence for the crucial role of miRNAs in all stages of cancer
pathogenesis. In metastasis, the important regulatory role of miRNA, and the impact of
deregulated microRNA expression on metastatic progression, has been well documented. The
importance of microRNAs in the regulation of epithelial-mesenchymal transition and
metastasis will be the focus here.

EMT is a dynamically regulated process and there are multiple levels through which
expression can be regulated. microRNAs are key, and their loss or gain of expression has
implications on EMT and metastasis. Figure 7 highlights some of the important miRNA
regulators in EMT. To elaborate on some of these; expression of both miR-21 and miR-9
promote metastasis, with miR-21 promoting invasiveness and metastasis in many cancers
(Cottonham, Kaneko, & Xu, 2010; D'Amato et al., 2013; Huang et al., 2013). Meanwhile
miR-9 directly controls E-cadherin expression as a pleiotropic pro-metastatic oncogene (Ma
et al., 2010; Zhang & Ma, 2012). Conversely, there are miRNAs whose expression can
suppress EMT, such as the miR-200 family whose role in metastasis will be described below.
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Figure 7. miRNA expression in EMT
Several microRNAs are important in maintaining EMT, whose expression may be
oncogenic and maintain a mesenchymal phenotype, or tumour suppressive whose
expression maintains epithelial phenotype. Expression of these miRNAs determines
whether the cell maintains an epithelial or a mesenchymal phenotype. (Image adapted
from D’Amato et al., 2013).

3.3.2 The miR-200 family and miR-200b in EMT
The miR-200 family consists of five members; miR-200a, miR-200b, miR-200c, miR-429,
and mir-141, belonging to two clusters on chromosome 1p36 (miR-200b/c and miR-429), and
12p13 (miR-200a and miR-141). They share highly conserved seed sequences which differ
by only a single nucleotide (Feng, Wang, Fillmore, & Xi, 2014) (Figure 8).

Figure 8. The miR-200 family members have two conserved seed sequences
Two clusters of the miR-200 family; miR-200b/c/429 and miR-200a/141, share seedsequences differing by a single nucleotide. (Sequences obtained from miRBase, 2014).
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In cancer, miR-200 functions as an important tumour suppressor. Loss of expression of the
miR-200 family is evident in many cancers, and is associated with poor survival, increased
cell proliferation, and in particular, an invasive/metastatic phenotype (Hailin et al., 2013;
Men, Liang, & Chen, 2014). Members of the miR-200 family are involved in the regulation
of EMT and maintaining an epithelial phenotype, with loss of expression most commonly
associated with a metastatic phenotype (Feng et al., 2014; Park, Gaur, Lengyel, & Peter,
2008). Reduced expression of miR-200b may be a consequence of altered epigenetic
mechanisms causing promoter hypermethylation affecting the miR-200b cluster which is
consistent with reduced expression in medulloblastoma.

Members of the miR-200 family specifically regulate the transcription factors (ZEB1 and
Zeb2), and form a negative regulatory feedback loop to regulate expression of the epithelial
cell adhesion molecule E-cadherin (Ding, 2014). To elaborate, ZEBs are negative regulators
of E-cadherin, and expression results in loss of the epithelial marker E-cadherin, which is
evident during EMT (Barry et al., 2008; Korpal, Lee, Hu, & Kang, 2008). miR-200 family
members are inhibitors of ZEBs, and their expression maintains epithelial phenotype.
Likewise ZEBs negatively regulate miR-200 and maintain mesenchymal cell phenotype. A
simplified overview of miR-200 role in EMT is presented below in Figure 9.

Figure 9. Simplified overview of the regulatory role of miR-200 in EMT
In epithelial cells; ZEB1 and ZEB2 are EMT-inducing transcription factors regulated
by miR-200, and repress the expression of E-cadherin. In epithelial cells, the miR200 family inhibits the expression of ZEB1 and ZEB2. Ultimately this enables
expression of E-cadherin and maintenance of the epithelial cell phenotype.
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Loss of miR-200 expression is predicted to be a vital step in the metastatic process, and
certainly this phenomenon may be important in highly metastatic cancers such as
medulloblastoma. Previously, the loss of miR-200 expression has been reported in metastatic
prostate cancer, breast cancer, colorectal cancer, lung cancer, gastric cancer, and others (Feng
et al., 2014). Different members of the miR-200 family alone, have been identified as
potential prognostic markers with a proposed prognostic role in glioma and breast cancer
(Men et al., 2014; Ye et al., 2014), and are able to regulate invasiveness individually. For
example, over-expression of miR-200b in prostate and gastric cancer results in reduced
invasiveness that is predicted to be due to reversal of EMT (Hailin et al., 2013; Williams,
Veliceasa, Vinokour, & Volpert, 2013a, 2013b). Although miR-200 expression has not been
investigated in medulloblastoma pathogenesis, given the role of deregulated expression of the
miR-200 family in promoting metastasis in various contexts suggests that loss of miR-200b
function may contribute to medulloblastoma pathogenesis and metastasis.

Medulloblastoma tumours have a high propensity to metastasise, with around 30% of
tumours showing dissemination at diagnosis, linked to poor prognosis (Gerber et al., 2014).
Therefore, effectively targeting metastatic medulloblastoma cells at a molecular level may
prove to be a valuable therapeutic. miRNA expression profiling in medulloblastoma cell lines
within this laboratory has revealed down-regulation of miR-200b in medulloblastoma cell
lines that are representative of the aggressive Group 3 sub-group, consistent with a potential
role in metastatic medulloblastoma. Additionally, in-silico analysis of the DACH1 3’-UTR
(TargetScan Human Release 6.2) revealed a potential binding site for nine miRNA/clusters
(Figure 10a). miR-200b was one of the miRs identified as having a high probability of
binding to the DACH1 3’UTR at position 971-978 in the 2689 nucleotide (nt) 3’UTR (Figure
10b).
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Figure 10a. TargetScan putative miRNA binding sites
TargetScan identifies nine clusters of miRNAs with potential binding sites in the
DACH1 3’UTR. Two have 8-mer binding sites with high probability of binding (hsamiR200b/c/429 and hsa-miR-153), while the remaining have a low probability 7-mer
and 8-mer potential binding sites

Figure 10b. miR-200 family target sequence within the DACH1 3’UTR
Members of the miR-200 family cluster miR-200b/c/429 have an 8-mer sequence
within the DACH1 3’UTR, with a high probability of binding. miR-200b is
highlighted.
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4.0

SUMMARY

The exact pathogenic mechanisms driving elevated DACH1 expression are unclear, but
current evidence suggests elevated DACH1 plays an important role in tumour growth,
progression, and metastasis. DACH1 is a putative oncogene in medulloblastoma, overexpressed in all four sub-groups of medulloblastoma, most noticeably in Group 4
medulloblastoma. Its previous links with metastasis supports the potential role of DACH1 in
progression of metastatic Group 4 medulloblastoma. In addition, it is possible that the overexpression of DACH1 is a consequence of aberrant epigenetic regulation, such as loss of
miRNA regulation. In medulloblastoma, miR-200b is down regulated, and has putative
binding site within the DACH1 3’UTR, suggesting a potential for miR-200b to be involved in
regulation of DACH1 expression.
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4.1

AIMS

We hypothesise that miR-200b regulates DACH1 and that this relationship is significant in
aggressive Group 3 and Group 4 medulloblastoma pathogenesis. Our aims therefore are:
1. To confirm an inverse correlation between DACH1 and miR-200b in
medulloblastoma cells using quantitative reverse transcription polymerase chain
reaction to assess miR-200b and DACH1 mRNA.

2. To generate reporter cell lines via stable transduction of a DACH1-3’UTR-lentireporter-GFP virus, and assess the effect of miRNA on reporter protein expression.

3. Transiently transfect cells with miR-200b, and assess for any changes in DACH1
mRNA or protein expression, using qRT-PCR and Western Blot.
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5.0

METHODS

5.1

Cell culture:

Medulloblastoma cell lines DAOY, UW228, PER547, D283, D341, and D425 cells were
cultured at 37oC, in 5% CO2 . These cells were maintained as follows:

Table 2 Cell line details and culture conditions

DAOY

Cell line details

Culture conditions

Representative of Sonic

Adherent cells, grown as a single monolayer

Hedgehog (SHH)

DMEM (Gibco®, Invitrogen™,

medulloblastoma

LifeTechnologies™, Carlsbad, Canada) +

(Jacobsen, 1985)

10%FCS + 1% Glutamax (Gibco®),
harvested with 0.05% dissociation reagent
(TrypsinEDTA) (Gibco®) and subcultured at
1:20 when cells reached 90% confluence

UW228

Representative of Sonic

Adherent cells, grown as a single monolayer

Hedgehog (SHH)

MEM (Gibco®) + 10% FCS + 1% Glutamax

medulloblastoma

(Gibco®), harvested with 0.05% trypsin,

(Keles, 1991)

subcultured 1:20 when cells reached 90%
confluence

PER547

Representative of Group 3

Suspension cells (1:6)

medulloblastoma

RPMI (Gibco) + 20% FCS + Glutamax

(Holthouse et al., 2008)

(Gibco®) + non-essential amino acids
(NEAA) 100x (Gibco®) + Sodium pyruvate
(NaP) 100nM (Gibco®)+ 1.8mL 2mercaptoethanol (2-ME) (Sigma Aldrich®,
St. Louis, Missouri), cells were subcultured
1:6 when 80-90% confluent

D283

Representative of Group 3

Semi-adherent cells (1:3)
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medulloblastoma

MEM (Gibco®) + 20% FCS + 1% Glutamax

(Friedman, 1985)

(Gibco®), cells were subcultured when 8090% confluent

D341

Representative of Group 3

Suspension cells. (1:3)

medulloblastoma

MEM (Gibco®) + 20% FCS + 1% Glutamax

(Firiedman, 1988)

(Gibco®), cells were subcultured when 8090% confluent

D425

Representative of Group 3
medulloblastoma
(He, 1991)

Semi-adherent cells. 1:5
Modified MEM (Gibco®) + 10% FCS + 1M
Hepes (Gibco®), cells subcultured when 8090% confluent

Adherent cells were harvested by removing medium then briefly washed in 5-10mL of DPBS
(Gibco®). 5-10mL of 0.05% dissociation reagent. Cells were incubated for 5 minutes at
37oC and then mechanically dissociated from plate. Cells were collected in a 5mL tube, then
diluted 1:20 and re-plated in a T25 flask (nunc) with 5mL of growth medium, or a T75 with
10mL of growth medium. Note that cells were re-plated while suspended in trypsin.

Semi-adherent/suspension cells were harvested by mechanical pipetting to dissociated cells
and collected in a 50mL Falcon tube. Cells were split in a 1:3-1:6 ratio depending on growth
rate. Cells were plated in 1mL of medium in a 24 well plate (nunc).

5.1.1

Countess: cell number and viability

10µL of harvested cells were aliquoted with 10µL of 0.2% Trypan Blue (TB) (Sigma
Aldrich®) (1:1 ratio). 10µL was then counted using the Countess™ automated cell counter
(Invitrogen™, Life Technologies™).
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5.2

Protein Extraction

1.0-4.0x106 cells were pelleted in using a HERAEUS Multifuge 35R+ (ThermoScientific,
Waltham, Massachusetts) at 900rpm for 5 minutes, and resuspended in PBS buffer (-Mg2+
and -Ca2+, Gibco®), then re-pelleted. Cells were lysed in 70µL radioimmunoprecipitation
assay (RIPA) buffer (150mM NaCl, 50mM Tris HCL pH8, 1% NP-40, 0.5% Sodium
deoxycholate, 0.1% SDS with complete mini EDTA free and phos-stop inhibitors (Roche,
Switzerland). The Lysate was then centrifuged 13,000rpm for 20minutes at 4oC (HERAEUS
Fresco17, ThermoScientific) to pellet debris, and protein was quantified using a Direct
Detect™ Spectrometer (Merck Millipore, Billerica, Massachusetts).

5.3

SDS polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting

Total protein (30µg), was adjusted to 20µl with the addition of 2µl 10x reducing agent and
5µl 4x loading buffer. Samples were denatured at 70oC and run on 3-8% Tris Acetate gel
(NuPAGE®, Life Technologies™) at 145V for 65 minutes at room temperature, in Tris
Acetate running buffer. Precision plus protein™ Dual Colour standards (BioRad, Hercules,
California).

Protein was transferred to BioRad 0.2µM nitrocellulose membrane (1620112) in 1x
NuPAGE® (Life Technologies™) transfer buffer, 20% methanol, at 30V for 120 minutes, at
4oC. Following transfer, membranes were stained with Ponceau S (0.1% Ponceau S, 7%
glacial acetic acid) to monitor efficiency of protein transfer. Membranes were subsequently
blocked for 1 hour at room temperature in blocking solution (5% skim milk powder in
1xTBS/0.1% Tween-20), and washed 3x5minutes in 1xTBS/0.1% Tween-20.

Primary antibody; rabbit anti-human DACH1 polyclonal antibody (10914-1-AP, raised
against amino acid residues 350aa in the C-terminus) (Proteintech™, Chicago), was diluted
1:1000 with 5µL in 5mL antibody diluent buffer (1% Skim milk powder, 1% BSA in
1xTBS/0.1% Tween-20) and incubated overnight (O/N) at 4oC on a shaker. Membrane was
washed 3x5min in 1xTBS/0.1% Tween-20.

36

The membrane was incubated with ECL Rabbit IgG, HRP-linked F(ab)2 secondary antibody
(NA9340V) (GE healthcare, Wisconsin), diluted 1:5000 with 1µL antibody in 5mL of
antibody diluent, for 1 hour at room temperature.

SuperSignal West Dura Extended Duration Substrate (ThermoFisher Scientific) was used for
signal detection, and immunoblots were visualised using ChemiDoc MP Imaging System
(Bio-Rad).

β-actin was used as a loading control; Primary antibody monoclonal anti β-actin antibody,
mouse (A1978) (Sigma Aldrich®), and ECL Mouse IgG, HRP-linked F(ab)2 secondary
antibody (NA9310V) (GE healthcare), diluted 1:5000, incubated at room temperature for 1
hour each and developed as described above.

5.4

Extraction of total RNA

In most cases, total RNA (including mRNA and miRNA) was extracted from cell lines using
a miRNeasy kit (QIAGEN, Cat No: 217004) following the recommended protocol for
isolation of miRNA-enriched total RNA.

Briefly, cells were harvested as described and pelleted by centrifugation (HERACUS
Multifuge35R, ThermoFisher) in a 25mL Falcon tube (BD Falcon, USA) at 900rpm for 5
minutes. Cells were washed once* in 1mL DPBS (Gibco®) (*Adherent cells were washed
twice) and counted using the Countess automated cell counter (Invitrogen™, Life
Technologies™) as described. DPBS (Gibco®) was removed and cells were resuspended in
350-700µL of QIAZOL lysis reagent (QIAGEN). To mix, the suspension was vortexed and
incubated at room temperature for 5minutes. Lysate was then extracted by adding 70-140µL
of Phenol-chloroform and incubating at room temperature for 2 minutes, then centrifuged
12000rpm/15 minutes (HERAEUS Fresco17, ThermoScientific). The upper phase was
removed (approximately 100µL) and added with 1.5 volumes of 100% ethanol. Washes were
performed with buffer RWT and buffer RPE and purified RNA was eluted in RNase-free
water and quantified using nano drop spectrophotometer (ThermoScientific). RNA with a
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260/280 ratio of >1.8 was considered to be of suitable quality and RNA integrity was further
assessed by electrophoresis on a 1.5% agarose gel.

5.5

TaqMan® Gene expression assays

Two-step quantitative reverse transcription polymerase chain reaction (qRT-PCR) was
performed to assess DACH1 mRNA expression in DAOY, UW228, PER-547, D283, D341,
and D425. Gene expression assays were performed as per TaqMan® (Applied Biosystems
ABI®, Life Technologies™) recommended protocol, using 200ng of total RNA in a 20µL
reaction, and reverse transcribed using SuperScript® VILO™ master mix (Invitrogen™, life
technologies™) with random primers.

Reverse transcription reactions were prepared using 4µL SuperScript® VILO™
(Invitrogen™) master mix with SuperScript® III Reverse Transcriptase and a final
concentration of 200ng/µL of total RNA. Conditions for RT were as follows:
25oC

10 minutes

42oC

1 hour, 40 minutes

85oC

5 minutes

The cDNA was then used to perform qPCR. Triplicate reactions were prepared with 1.33µL
of cDNA preparation , 20x TaqMan® gene expression assay for DACH1 (ABI®, Life
Technologies™, Cat#: 4351372) and GAPDH (ABI® Life Technologies™, Cat# 4331182),
2x TaqMan® universal PCR master mix (No AmpErase® UNG), and nuclease-free water.
20µL samples were then plates and run on ABI® 7900HT Fast Real-Time PCR system using
SDS version 2.3 software (ABI®), and the comparative Ct (Cycle threshold) (ΔΔCt) method.
Cycling conditions for qPCR were as follows:
Stage 1 (HOLD)
Stage 2 (40 cycles)

95oC

10 minutes

95oC

15 seconds

60oC

1:00 minute
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5.6

TaqMan® microRNA assays

Total RNA was prepared using an miRNeasy (microRNA extraction) kit (QIAGEN) and
quantified, as previously described. Total RNA was diluted to 2ng/µL in RNase-free water, to
give a final concentration of 10ng/µL total RNA per reaction. RNA for reverse transcription
was prepared in singleplex reactions with miRNA-specific primers for miR-200b (target and
RNU44 (internal control) and RNU48 (internal control) (ABI®, Life Technologies™, Cat#:
4427975). TaqMan® miRNA reverse transcription (RT) master mixes (ABI®, Life
Technologies™) with MuLV RT were prepared as singleplex reactions using specific 5x RT
primers specific for the miR-200b 3p strand, RNU44 and RNU48.

Per 15µL reaction using, 7µL of master mix was made up as follows
0.15µL of 100mM ddNTP
1.00µL of 50U/µL MultiScribe™ reverse transcriptase
1.50µL of 10x RT buffer
0.19µL of 20U/µL RNase Inhibitor
4.16µL RNase-free water

MasterMix and RNA were combined at a ratio of 7µL:5µL + 10%, with 7.7µL + 5.5µL.
12µL of MasterMix plus RNA war combined in a 0.2mL PCR tube, with 3µL of primer and
gently mixed.

RT was carried out using recommended thermo cycling conditions:
On Ice 5 minutes
16oC

30 minutes

42oC

30 minutes

85oC

5 minutes
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Reverse transcribed miRNA was then used to perform qPCR. These were set up in triplicate,
with each individual reactions were prepared with 1.33µL of cDNA preparation (1:15
dilution), 1µL 20x TaqMan® microRNA expression assay for miR-200b, or 1.0µL of 20x
TaqMan® microRNA expression assay for RNU44/RNU48 (ABI® Life Technologies™,
Cat#: 4427975), 10.0µL 2x TaqMan® universal PCR MasterMix (No AmpErase® UNG),
made to a final volume of 20L with 7.67µL of nuclease-free water. The 20µL samples were
then plates and run on ABI 7900HT Fast Real-Time PCR system using ABI® SDS version
2.3 software (ABI®, ©2005), and the comparative Ct (ΔΔCt) method. Cycling conditions for
qPCR were as follows:
Stage 1 (HOLD)

95oC

10 minutes

Stage 2 (40 cycles)

95oC

15 seconds

60oC

1:00 minute

All qRT-PCR data was collected using ABI® RQ manager version 1.2 software (ABI®,
©2005), and further analysed using Microsoft Excel.

5.7

Lentiviral Transductions

Transductions for the following were attempted:
(i)

Cell lines with low levels of mir-200b were transduced with a hsa-miR-200bGFP-lenti reporter (Applied Biological Materials (ABM®) Inc., New York City,
USA) (Cat#: Mh-15262).

(ii)

All cells were transduced with a DACH1-3’UTR-GFP-Lenti reporter virus
(ABM® Inc., Cat#: MV-05537). See Figure 11a and 11b for vector constructs.

Protocol supplied by ABM® Inc. was followed, with adjustments made for optimisation.
Following the ABM protocol, cells were seeded the day before transfection at a density of
0.5x105 cells per well.

On the day of transfection, cells were harvested and pelleted as usual, then resuspended in
medium containing 8µg/mL of polybrene, and various amounts of viral medium were added.
Also included were a GFP control lentivirus, and a negative control pLenti-III-Lentivirus
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(ABM® Inc., Cat#: LVPS87) (Figure 11c). Controls for polybrene toxicity and another of
uninfected cells were used as controls. Cells were incubated for 24 hours, then medium was
removed and replaced with normal growth medium. Cells were incubated for a further 48
hours and then selected for with 2µg/mL of puromycin. A puromycin control was included.

Small adjustments were made to this, including cell numbers- cells were plated at a density
such that they would be ~80% confluent, 72 hours after transfection (adherent cells were
seeded at a density of 1.4x105 cells/T25 flask (Nunc), and semi-adherent cells were plated at
a density of ~1.0x105 cells/well in a 24-well plate (Nunc). Virus was also removed after 3-4
hours of incubation. Cells were allowed to recover for three days before selection.
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Figure 11a. DACH1-3’UTR-Lenti-reporter-GFP viral vector

Figure 11b. Lenti-miRa-GFP-hsa-miR-200b viral vector

Figure 11c. pLenti-III-blank-lentiviral vector

Lentiviruses were obtained commercially from ABM® Inc. All three include a CMV
promoter, and contain puromycin resistance (Puror) gene for cell selection. DACH1-3’UTRGFP-lenti reporter viruses also contain a Green fluorescent protein gene (GFP) linked to the
DACH1 3’UTR for assessment of reporter expression with high or low miR-200b expression.
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5.8

Cloning

5.8.1 Transformation of E. coli
One Shot® TOP10 chemically competent E. coli (Invitrogen™, Life Technologies™) were
transformed with 2ng of DACH1 3’UTR lenti-reporter-Luc Vector plasmid (ABM® Inc,
Cat#:MT-h05537) (Figure 12.). Briefly, cells were combined with plasmid and incubated on
ice for 30 minutes, transferred to 42oC for 30 seconds, and then kept on ice for 2 minutes. For
recovery, 250µL S.O.C medium was added and cells plus medium were transferred into a
15mL Falcon tube (BD Falcon) and incubated in a shaker at 250rpm, 37oC overnight.

Following overnight incubation, 50µL, 100µL, and 150µL of cells were plated on LB agar
plates containing Kanamycin (50µg/mL) and incubated at 37oC overnight. Plates were then
stored at 4oC.

Two separate colonies were picked and used to inoculate individual 15mL falcon (BD
Falcon) tubes containing 2 mL of LB broth/50µg/mL Kanamycin. These cells were incubated
on a shaker at 250rpm at 37oC overnight. 100µL of the overnight mini prep culture was added
to a conical flask containing 100mL of LB/ 50µg/mL Kanamycin broth and cultured at 37oC
overnight.

Following overnight culture, the cells were transferred into two 50mL falcon tubes and
centrifuged 4000rpm for 10 minutes.

Plasmids from transformed cells containing the DACH1 3’UTR lenti-reporter-Luc plasmid
(ABM® Inc.), and pre-prepared cells containing pCAG-KPGY Gagpol plasmid, pCAGVSVG envelope plasmid, and pCAG-RTR revtat plasmid (supplied by Dr Jacqueline
Whitehouse) were isolated using Plus midiprep kit (QIAGEN) high efficiency protocol.
Plasmid DNA quality was then assessed using the nanodrop spectrophotometer (Thermo
Scientific) and stored at -20oC.
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Figure 12. pLenti-DACH1-3’UTR-Luc-reporter vector
The pLenti-DACH13’UTR-luciferase-reporter vector was purchased from Applied
Biological Materials Inc. (ABM). The vector contains a Kanamycin resistance (Kanr)
gene used to select for transformed bacterial colonies, a Puromycin resistance (Puror)
gene for selecting transduced cells, and a luciferase reporter linked to the 3’UTR for
assessing reporter expression in the presence of high and low levels of miR-200b.

5.9

Generation of lentivirus

To generate lentivirus, Human Embryonic Kidney 293T (HEK-293T) cells were transfected
with reporter and packaging plasmids, according to the following procedure (supplied by Dr
Jacqueline Whitehouse):

On day one, 3x106 293T cells were plated in a 10cm culture dish with DMEM (Gibco®) +
1% (v/v) Penicillin/Streptomycin (pen/strep) (Gibco®) 1% (v/v) + 10% (v/v) FCS.

Day 2, plasmid DNA was combined in serum-free DMEM (Gibco®) and vortexed to mix.
DNA was added at the following amounts:
12µg of vector plasmid (DACH1 3’UTR-lenti-reporter-Luc vector)
6µg of gagpol plasmid (pCAG-KPGY)
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2µg of envelope plasmid (pCAG-VSVG)
2µg of revtat (pCAG-RTR)

FuGene 6® transfection reagent (Promega) was diluted in serum-free DMEM and vortexed to
mix. FuGene and plasmid DNA were combined and added to cells with 8mL of fresh DMEM
medium (Gibco®) + 1% Pen/Strep (Gibco®) + 1% Glutamax (Gibco®) + 10% FCS, and
incubated 37oC for 24hours.

Day 3, media was removed and replaced with 5mL of DMEM medium (Gibco®) + Pen/Strep
(Gibco®)+ Glutamax (Gibco®) + 10% FCS, and incubated 37oC/5% CO2 for a further
24hours.

Day 4, 48 hours following transfection, the 48 hour viral supernatant was collected and stored
on ice at 4oC overnight. 5mL of fresh DMEM medium (Gibco®) was added to cells.

Day 5, 5mL of 72 hour viral supernatant was collected and combined with 48 hour
supernatant, and filtered through a 0.45µm filter syringe, then stored at -80oC.

5.10 Transfections
SiGlo green transfection indicator (Dharmacon, GE Healthcare, Cat#: D-001630-01-20),
20nmol dry stock, and mirVana hsa-mir-200b-3p mimics 5nmol dry stock (Ambion®, Life
Technologies™, Cat#:4464066) were resuspended to a final concentration of 50µM, by
adding 400µL, and 100µL of RNase-free water, respectively.

The Neon® electroporation system (Invitrogen, Cat#MPK5000) was use to conduct
transfection, using 10µL Neon® tips (Invitrogen, Cat#MPK1096). 10µL of transfected cells
were plated in 490µL of growth medium to a final volume of 500µL, in a 24 well plate.
Optimal transfection conditions for D283 and D341 had previously been determined, with
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successful transfection with 1 pulse at 1350 volts (V), 20 milliseconds (ms). These conditions
were also found to be optimal for transfection of PER547 and D425.

Following the recommended protocol, cells were plated 1-2 days prior to transfection in
normal growth medium. The following day cells were harvested and pelleted by
centrifugation at 400xg for 5 minutes (ThermoScientific). Cells were counted on the countess
(Invitrogen™), as previously described, and washed in PBS buffer (no MgCl2). Cells were
resuspended in buffer R (Invitrogen™) to a density of 1.0x107 cells/mL, and mixed well to
create a single cell suspension. 13µL aliquots of cell suspension were added with 2.6µL (or
6.5µL) of 50µM of hsa-mir-200b-3p mirVana mimic (Ambion®) (hereafter referred to ‘miR200b mimic’) or miRNA negative control#1 (hereafter referred to as ‘control’) (Ambion®)
and gently pipetted to mix. 10µL of cell mix was electroporated in 5mL of Buffer E
(Invitrogen™) using conditions of 1350V, 1 pulse, 20ms. Electroporated cells were then
plated in 490µL of pre-warmed culture medium, with miR-200b mimic/control at a final
concentration of 20nM or 50nM). A total of 12 wells were plated for both the mimic and
control. SiGlo was used as a transfection indicator to determine transfection efficiency. SiGlo
(Dharmafect GE healthcare) was transfected to a final concentration of 20nM in 500µL using
the same conditions.

Following 24-48 hour incubation, cell fluorescence of SiGlo (Dharmafect GE healthcare)
transfected cells was assessed using the Tali™ image based cytometer (Invitrogen™). A
control sample of un-transfected cells and a sample of SiGlo transfected cells were assessed.
If cell fluorescence was >75%, transfected cells were harvested, and protein and RNA were
extracted as described above, for downstream mRNA, miRNA, and protein analysis.

5.10.1 Lipofectamine® RNAiMAX transfection
The recommended protocol was followed for transfection of DAOY cells using
Lipofectamine® RNAiMAX Lipofectamine transfection (Invitrogen™, Cat#: 13778500).

In separate tubes, 9µL of RNAiMAX (Invitrogen™) or 1.2µL of 50nM SiGlo were diluted
into 150µL of OptiMEM (Gibco®) reduced serum medium. 150µL of both diluted SiGlo and
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RNAiMAX were combined in a 1:1 ratio and incubated at room temperature for 5 minutes to
allow complexes to form. 250µL of combined solution was then added drop-wise to cells,
into a final volume of 250µL, giving a final concentration of 20nM.

Cells were incubated for at least 24 hours and fluorescence was then assessed using the
Tali™ image based cytometer (Invitrogen™) as described below.

5.10.2 Tali™ Image based cytometer
Cells were harvested 24 hours following transfection and fluorescence was assessed by
transferring a 25µL aliquot of cells onto a Tali™ slide (Invitrogen™). An un-transfected
sample was assessed to obtain a background measure. Gates were set so that 0% fluorescence
was detected in control un-transfected cells. Transfected cells were then assessed using Green
fluorescent detection and a right hand shift of the curve indicated positive transfection. A
percentage value of fluorescent cells was then obtained. Cells with ≥70% fluorescence were
used for downstream expression analysis.

5.11 Data analyses
5.11.1 qRT-PCR expression data
qRT-PCR data was collected using ABI® RQ manager version 1.2 software, and exported to
excel for analysis. Relative Quantitation (ΔΔCt) analysis was performed, as previously
described. Briefly, average Ct values from two to three independent experiments, with two to
three replicates per-experiment were collected. Average Cts ≥32 were given a value of zero
to represent no expression.

Normalised expression between the Gene of Interest (GOI), DACH1 and miR-200b, and the
Internal control GAPDH, and RNU44/RNU48, was calculated as ΔCt value where ΔCt=
CtGOI – CtInternal Control. For post-transfection analysis, the ΔCt was adjusted to 2-ΔCt and Log2
transformed to give a value representing normalised expression (target relative to control).
For the base-line analysis, relative quantitation (RQ) was determined using D283 as a
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normalised. This was calculated as ΔΔCt= ΔCtGOI – ΔCtnormaliser (D283), and adjusted 2-ΔΔCt and
Log2 transformed.

Standard deviation (SD) was calculated as the SD between the target and control = (GOI SD2
+ internal control SD2)0.5. The Ct SD was presented as error bars.

5.11.2 Western blot and protein quantification
Membranes were probed with primary and secondary antibodies, and protein was detected
using SuperSignal® WestDura Extended duration substrate (ThermoFisher Scientific).
Immunoblots were visualised using the ChemiDoc MP imaging system (BioRad), and were
presented in BioRad ImageLab 5.1 software.

Relative protein was determined by assessing the quantity of DACH1 to the β-actin control.
Quantity was determined based on band intensity. Normalisation to β-actin was carried out as
band intensity of DACH1 band-band intensity of β-actin band, and Log2 transformed.
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6.0

RESULTS

6.1

An inverse correlation between DACH1 and miR-200b expression in
medulloblastoma cell lines

The DACH1 3’UTR contains a putative binding site for miR-200b (see Figure 10.)
suggesting that miR-200b may target the DACH1 transcript. To address this, miR-200b and
DACH1 expression were assessed in six medulloblastoma cell lines, using two-step
quantitative reverse transcription polymerase chain reaction (qRT-PCR). Ct values ≥32 were
considered negligible or no expression. An inverse correlation between levels of DACH1
mRNA and miR-200b was detected in 5/6 cell lines, with D425 being the exception (Figure
13.).

For analysis, expression was normalised against an internal control; GAPDH was the internal
control used for normalisation of DACH1 expression in all cell lines, RNU44 was used as an
internal control for miR-200b in D341, PER547, and D283, while RNU48 was an internal
control in D425. D425 was normalised to the internal control RNU48 due to RNU44 having
higher Cts compared to the other cell lines. RNU48 also had higher Ct values than RNU44 in
the other five cell lines, skewing the normalisation of D425. Original, un-normalised Ct data
(Appendix B.) demonstrates that miR-200b expression is relatively consistent across all cell
lines, including D425.

The comparative Ct (ΔΔCt) method was used for normalisation of expression, presented as
DACH1 or miR-200b expression normalised to the appropriate internal control, and relative
to D283 cell line. This method was previously described by (Livak & Schmittgen, 2001;
Schmittgen & Livak, 2008). Figure 13 presents the normalised levels of DACH1 and miR200b in each of the cell lines that were investigated. A summary of their expression is
presented in Table 3.

DACH1 protein was detected using western blot to confirm expression at the protein level.
Consistent with the qRT-PCR data, a prominent band of ~97kDa, the predicted size of the
DACH1 protein was detected in PER547 and D341, and lower levels of DACH1 protein were
present in D425 and D283. DACH1 protein was not detected in DAOY or UW228
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Figure 13. Expression of DACH1 and miR-200b in medulloblastoma cell lines,
relative to D283.
An inverse correlation between the expression of DACH1 mRNA and miR-200b was
evident in the majority of cell lines (5/6). Total RNA and miRNA-enriched RNA were
extracted from all cells, and expression was assessed using qRT-PCR. Each extraction
was repeated three times, with two to three replicates for each cell line for each qRTPCR experiment. The results were analysed using relative quantitation, with average
cycle threshold (ct) values normalised against a respective internal control; for DACH1,
GAPDH was used as the internal control in all cell lines, and for miR-200b, RNU48
was used as an internal control for D425, while RNU44 was used as the internal control
for the remaining cell lines. Normalised expression was determined relative to D283.

To highlight the inverse correlation, no cut-off ct value was applied here, however
DACH1 expression in DAOY, and miR-200b expression in PER547, D283, D341, and
D425 all had ct values ≥32, which was designated as ‘no expression’. The error bars
represent standard deviation (SD) between ct values from each independent experiment.
SD was calculated as (SD DACH12 - SD GAPDH2)0.5 or (SD miR-200b2 – SD
RNU44/482)0.5.
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DACH1 protein expression
Figure 14. DACH1 protein expression in six representative medulloblastoma cell
lines with quantitative analysis of protein expression
(a.) DACH1 protein was detected in the four cell lines that also showed elevated
DACH1 mRNA expression, and was not detected in DAOY and UW228. β-actin was
used as a loading control, and indicated that higher levels of protein were loaded for
DAOY, UW228, and D283. (b.) Additional quantitative analysis of DACH1 protein
expression was performed, relative to β-actin. PER547 and D341 expressed high levels
of DACH1, D425 and D283 expressed lower levels, while no DACH1 protein was
detected in DAOY and UW228.
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Table 3. Simplified summary: an inverse correlation exists between DACH1 and miR200b
DACH1

miR-200b

DAOY

Low

High

UW228

Low

High

PER547

High

Low

D283

High

Low

D341

High

Low

D425

High

Low

A summary of DACH1 and miR-200b expression, showing an inverse correlation between
DACH1 and miR-200b that is based on average Ct data (Appendix B).
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6.2

Addressing the inverse correlation between DACH1 and miR-200b

6.2.1 Stable transductions with Lentivirus
Lentiviral transductions using commercially obtained lentiviruses DACH1 3’UTR LentiReporter-GFP virus, and Lenti miRa-GFP-hsa-mir-200b virus (Applied Biological Materials
Inc. (ABM) were attempted in cell lines with low endogenous miR-200b expression.
However, due to unexpected problems with commercially purchased DACH1-3’UTR-GFPLenti reporter viruses, reporter cell lines were not generated. This was due to evidence of
bacterial contamination of viral stocks. Contamination was suspected following high levels of
cell death occurring 72-96 hours after transductions but prior to puromycin selection.
Importantly, this occurrence was only identified in cells that were inoculated with the
purchased lentivirus.

To further confirm the source of contamination, culture medium was inoculated with viral
medium, and produced visible growth of bacteria 72-96 hours after inoculation, which was
not detected in medium alone. Cells were cultured in 1% Penicillin/Streptomycin and
maintained post-transduction however this did not prevent outgrowth of bacteria.
Consequently a new approach was needed in order to assess the potential association between
DACH1 and miR-200b.

DACH1-3’UTR-Luc-lenti reporter plasmids (Figure 12.) were purchased from ABM Inc. and
used to generate lentiviruses. DAOY cells proved easy to transduce and produced puromycinresistant colonies. This indicated that the virus was capable of infecting cells and was then
applied to semi-adherent cells with low miR-200b expression. These cells proved difficult to
transduce and puromycin resistant colonies were not detected after repeat attempts. Due to
time constraints, this protocol was not optimised, and therefore no data were collected.

6.2.2 Transient transfection of selected medulloblastoma cell lines
The difficulties associated with the viral transduction strategy described above, necessitated
an alternative approach for the manipulation of miR-200b levels in medulloblastoma cell
lines. A second approach to assessing whether DACH1 was targeted by miR-200b involved
transient transfection of mir-200b mimic and antagomirs. Cell lines with low levels of
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DACH1 expression, and high levels of miR-200b expression based on raw Ct values
(Appendix B), were to be transfected with miR-200b antagomirs, however, as described in
section 6.2.5, no optimised protocol was developed for these cell lines and transfection with
miR-200b antagomirs was not conducted. Cell lines with high levels of DACH1 expression,
and low miR-200b expression based on raw Ct values (Appendix B), were selected for
further analysis. These cell lines included D341, D425, PER547, and D283.

Firstly, optimal transfection conditions were tested for PER547 and D425, while previously
optimised conditions were available for D283 and D341. Transfection conditions used for
D283 and D341 also produced the highest transfection efficiency in PER547 and D425. To
determine transfection efficiency, cells were transfected with SiGlo fluorescent green
transfection indicator at a final concentration of 20nM, and fluorescence was assessed
following a 24 hour incubation. Further analysis was performed when transfection efficiency
of SiGlo control cells was ≥75%.

Cells were transiently transfected with a final concentration of 20nM of hsa-mir-200b-3p
mirVana mimic or miRNA negative control#1, and a final concentration of 50nM of hsa-mir200b-3p mirVana mimic or miRNA negative control#1.

Protein and miRNA-enriched RNA were extracted at both 24 hours and 48 hours posttransfection, for expression analysis.

6.2.3 Confirming miR-200b expression post-transfection
qRT-PCR was used to confirm whether miR-200b expression was restored following
transient transfection of these cell lines. Successful restoration of miR-200b expression was
confirmed following transfection with 50nM and 20nM mimic, by calculating Ct averages for
miR-200b and RNU44/RNU48, and normalising miR-200b expression to RNU44 (RNU48 in
D425) to obtain a ΔCt value for mir-200b mimic, and negative control transfected cells.
Normalised miR-200b expression in cells transfected with mir-200b mimic was compared to
the corresponding cell line transfected with negative control#1. These data were presented as
Log2 transformed 2-ΔCt values.
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6.2.4 Determining inhibition of DACH1 by miR-200b
To address the predicted targeting of DACH1 by miR-200b, hsa-mir-200b-3p stem loop
mirVana mimics were transiently transfected into 4/6 medulloblastoma cell lines with low
endogenous miR-200b, and relatively high DACH1 mRNA and protein (Table 3.). Two
concentrations were selected; 50nM and 20nM

6.2.5 Optimising transfection of adherent medulloblastoma cell line
The adherent cell lines DAOY and UW228, had higher levels of miR-200b expression and
lower DACH1 expression based on raw Ct values (Appendix B.), and therefore were selected
for transfection with hsa-mir-200b-3p mirVana antagomirs (mir-200b antagomirs).
Identification of optimal NEON transfection conditions for DAOY and UW228 cell lines was
attempted using 5-20nM SiGlo as an indicator of positive transfection. Optimisation was
attempted using conditions recommended by the manufacturer, however cells proved difficult
to transfect using this method, with transfection efficiency between 2-30% positive cells,
depending on the conditions used. The reasons for low transfection efficiencies using this
approach were unclear, and no optimised protocol using the NEON was generated. As an
alternative, transfections were attempted using the lipofectamine-based RNAiMAX. The
recommended protocol was followed, however transfection was unsuccessful. Due to time
constraints an optimised protocol was not developed, and consequently transfection of mir200b antagomirs could not be completed.
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Figure 15. Successful transient transfection of cell lines with 20nM and 50nM of
hsa-mir-200b-3p mimic, confirmed by qRT-PCR
miRNA enriched RNA was extracted from four cell lines, 24 and 48 hours posttransfection with 20nM of either hsa-mir-200b-3p mirVana mimic (mir-200b mimic) or
miRNA negative control#1 (control). qRT-PCR was performed to assess miR-200b
expression post-transfection with mir-200b mimic, relative to matched control cells
transfected with the control. (a.) miR-200b expression in cell lines, 24 hours posttransfected with 20nM of mir-200b mimic. (b.) miR-200b expression in cell lines, 48
hours post-transfection with 20nM of mir-200b mimic. (c.) miR-200b expression in cell
lines, 24 hours post-transfection with 50nM mir-200b mimic.

Expression was normalized against RNU44 as the internal control for D341, PER547,
and D283, and RNU48 as the internal control for D425. Average cycle threshold values
(Cts) were included from two independent transfection with three replicates each, with
Ct values ≥32 being considered as no expression, to eliminate the possibility of
detecting background noise. The relative quantity of normalised miR-200b expression
in cells transfected with mir-200b mimic was compared matched control cell line
transfected with negative control. Transfections successfully restored miR-200b levels
in all cells transiently transfected with mir-200b mimic.

Change in expression is presented as hsa-mir-200b-3p mimic transfected cells relative
to the matched miRNA negative control#1 transfected cells (2-ΔΔCt). The error bars
represent standard deviation between Ct values for each cell line (Ct SD calculated as
(SD mimic2 + SD control2)0.5).
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Figure 16. DACH1 mRNA expression is not affected by miR-200b expression in
cells transiently transfected with 20nM of miR-200b mimic, at 24 hours and 48
hours post-transfection.
Cell lines were transfected with 20nM of mir-200b mimic or 20nM of control. Two
independent transfections were performed, and miRNA-enriched mRNA was extracted
for analysis at 24 hours and 48 hours post-transfection. Both DACH1 mRNA and miR200b expression were assessed in cell lines transfected with miR-200b mimic and
control, using qRT-PCR. Each qRT-PCR reaction was performed in either duplicate or
triplicate, and average Ct values were analysed, using GAPDH, RNU44, and RNU48 as
internal controls. Normalised expression of miR-200b is presented as Log2 transformed
2-ΔCt, and normalised expression of DACH1 is presented as Log2 transformed 2ΔCt.
Error bars represent Ct SD; (Ct SD calculated as (SD mimic2 + SD control2)0.5).

58

Mir-200b expression did increase, however no change in the DACH1 mRNA levels
was observed at either time point.

59

a.
Mimic

Control

Mimic

D341

Control

Mimic

D425

Control

Mimic

PER547

Control

D283

e

DACH1

β-actin

b.

30

20
15
10

5
D283 control

D283 mimic

PER547 control

PER547 mimic

D425 control

D425 mimic

D341 control

0
D341 mimic

Log2 normalised expression

25

DACH1 protein expression in cells transfected with hsa-miR-200b-3p mimic
DACH1 protein expression in cells transfected with miRNA negative control #1

60

c.
Mimic

Control

Mimic

D341

Control

Mimic

D425

Control

Mimic

PER547

Control

D283

DACH1
β-actin

d.
Log2 normalised expression

30
25
20
15
10
5

D283 control

D283 mimic

PER547 control

PER547 mimic

D425 control

D425 mimic

D341 control

D341 mimic

0

DACH1 protein expression in cells transfected with hsa-miR-200b-3p mimic
DACH1 protein expression in cells transfected with miRNA negative control #1

Figure 17. DACH1 protein expression does not appear to be translationally
repressed in cells transiently transfected with 20nM of miR-200b mimic,
compared to cells transfected with 20nM of control, at 24 and 48 hours posttransfection.
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Protein lysate was collected from cells transfected with 20nM of mir-200b mimic or
control, at (a.) 24 hours and (c.) 48 hours post-transfection. Western blot was used to
detect protein expression and determine if DACH1 protein expression was downregulated following restoration of miR-200b expression. Bands were detected at
97kDa- the expected size of the full length DACH1 protein, and did not appear to show
reduced intensity in cells transfected with miR-200b mimic compared to cells
transfected with the control at either time point. β-actin was used as the loading control,
and showed relatively even loading across all lanes.

Quantitative analysis was then performed for protein expression (b.) 24 hours and (d.)
48 hours post-transfection, with DACH1 band intensity normalised against β-actin band
intensity in miR-200b and control-transfected cells, then Log2 transformed.
Quantitative analysis also did not indicate significantly reduced DACH1 expression at
either time point.
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Figure 18. DACH1 mRNA expression is not affected by miR-200b in cells
transiently transfected with 50nM hsa-mir-200b-3p mimic at 24 hours posttransfection.
50nM of mimic was transfected into four representative cell lines and miRNA enriched
RNA was extracted at 24 hours post transfection for expression analysis using qRTPCR to determine miR-200b and DACH1 mRNA expression relative to RNU44/48 and
GAPDH. Two independent experiments were performed, and two to three replicate
were performed. Ct values from replicates in both experiments were averaged and
normalised against the appropriate internal control, then Log2 transformed. At this time
point and this concentration, DACH1 levels remained relatively unchanged in cells
transfected with mir-200b mimic, compared to those transfected with the control.

63

a.
Mimic

Un-

Mimic

D341

Un-

Mimic

D425

Un-

Mimic

PER547

Un-

D283

b.
Log2 normalised expression

30

25
20
15
10
5
D283 control

D283 mimic

PER547 control

PER547 mimic

D425 control

D425 mimic

D341 control

D341 mimic

0

DACH1 protein expression in cells transfected with hsa-miR-200b-3p mimic
DACH1 protein expression in cells transfected with miRNA negative control #1

Figure 19. DACH1 protein expression does not appear to be translationally
repressed in cells transiently transfected with 50nM of miR-200b mimic,
compared to un-transfected cells, at 24 hours post-transfection
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(a.) Protein lysate was collected from un-transfected cells (Un-), and cells transfected
with 50nM of mir-200b mimic 24 hours post-transfection, and used for western blot
analysis to detect DACH1 protein expression, and assess for any variation in
expression. A band at approximately 97kDa was detected, and indicates reduced band
intensity in cells transfected with miR-200b as compared to the un-transfected control.
β-actin was used as a loading control with relatively even amounts of protein present in
each lane (b.) For quantitative analysis, the intensity of DACH1 bands were normalised
against intensity of the internal control β-actin, and then Log2 transformed.
Quantitative analysis also suggests a reduction in DACH1 at the protein level, in cells
transiently transfected with mimic.
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7.0

DISCUSSION

7.1

DACH1 and miR-200b expression are inversely correlated in medulloblastoma
cell lines

DACH1 expression has not previously been specifically investigated in medulloblastoma, but
previous genome-wide transcriptional profiling indicated elevated expression of DACH1
relative to normal cerebellum in all four medulloblastoma sub-groups. Notably, DACH1
expression was significantly higher in Group 4 relative to the other three sub-groups (Mark
Remke, University of Toronto. Pers comm). DACH1 mutations were not detected in
medulloblastoma genome sequence analyses (Parsons et al., 2011; Robinson et al., 2012) and
rarely identified in analyses of other cancers (COSMIC database, COSG74875). This
suggests a potential oncogenic role of epigenetic up-regulation of DACH1 expression, such
as by reduced DNA methylation (Hovestadt et al., 2014). Analysis of miRNA expression in a
small panel of human medulloblastoma specimens performed in the Brain Tumour
Laboratory at the Telethon Kids Institute, indicated that miR-200b was down-regulated in
Group 4 medulloblastoma (Genovesi et al., 2011). Similar to DACH1, reduced expression of
miR-200b may be a consequence of altered epigenetic mechanisms causing promoter
hypermethylation affecting miR-200 family cluster and miR-200b, which is frequently downregulated in cancer. This reduced expression is associated with early stages of metastasis
linked to de-regulated EMT (Feng et al., 2014). Here it was predicted that DACH1 was
regulated by miR-200b and that elevated DACH1 was a result of reduced miR-200b
expression, potentially associated with the increased metastatic propensity of Group 4
medulloblastoma.

Additional in silico analysis of the 3’UTR of DACH1 using the TargetScan algorithm
identified potential binding sites for nine miRNAs/clusters. Of these, the miR-200b/c/429
cluster was identified as having high probability of binding with a predicted 8-mer binding
site from nucleotides 971-978 (Figure 10a and 10b). These correlative data are suggestive of
DACH1 being a target of miR-200b. To address this possibility in vitro, DACH1 and miR200b expression were assessed in six medulloblastoma cell lines. The results demonstrated an
inverse correlation between DACH1 and miR-200b in these cell lines. Specifically, we
showed that in cell lines with elevated DACH1, miR-200b was reduced, and vice versa
(Figure13.). Western blot analysis for DACH1 protein expression in these cell lines was
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consistent with DACH1 expression at the mRNA level, and was inversely correlated with
miR-200b expression. This further supported the potential relationship between the
expression of DACH1 and miR-200b.

The elevated DACH1 expression observed in four of our cell lines representing Group 3
medulloblastoma is consistent with previous studies that showed a significant increase in
DACH1 levels in all sub-groups of medulloblastoma, particularly Group 3 and Group 4,
relative to normal cerebellum. It can be speculated that this elevated expression may be a
consequence of deregulated epigenetic mechanisms, such as reduced methylation of the
DACH1 promoter or regulatory elements. This has been suggested previously (Hovestadt et
al., 2014). Regulation by microRNAs is another possibility, given that there are numerous
over and under-expressed microRNAs involved in medulloblastoma pathogenesis. Members
of the miR-200 family in particular are of interest, given their well-described role in
metastatic cancers (Park et al., 2008; Zhang & Ma, 2012), and putative binding site within the
DACH1 3’UTR. Tentatively, reduced expression of miR-200b would correspond with the
metastatic phenotype of Group 4 medulloblastoma (Davalos et al., 2012). Both DACH1 and
miR-200b are linked with EMT, through the regulation of the transcription factors Snail and
ZEB (Barry et al., 2008; K. Wu, Chen, K., Wang, C., et al., 2014), ultimately controlling Ecadherin expression (Davalos et al., 2012).

It is important to note here that our experiments were carried out using cell lines representing
Group 3 medulloblastoma, rather than Group 4. However, it is evident that some Group 3
tumours expressed higher levels of DACH1. Additionally, an association was still seen
between DACH1 and miR-200b levels. This suggests that a potential relationship between
DACH1 and miR-200b also exists in Group 3 medulloblastoma, however, there may be
underlying differences in the mechanisms associated with altered expression

To our knowledge, DACH1 has not yet been verified as a target of miR-200b in any context.
Here, we speculate that in medulloblastoma, DACH1 is a target of miR-200b, and that
reduced miR-200b results in elevated DACH1, and this may be linked to Group 4
medulloblastoma pathogenesis. This warranted further investigation to determine whether
DACH1 is a bona-fide target of miR-200b.
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7.2

Stable lentiviral transduction to generate reporter cell lines

To address whether DACH1 is a bona fide target of miR-200b, we attempted to transduce our
medulloblastoma cell lines with a DACH1-3’UTR-GFP-Lenti reporter virus, to confirm
direct targeting by miR-200b. However, issues with contamination of commercial viral stocks
prevented these experiments from being carried out. Initially, the high amount of cell death
observed following transduction was assumed to be due to poor transduction efficiency,
resulting in low numbers of puromycin resistant cells. Optimisation experiments were carried
out using different viral MOIs and longer recovery times following transduction, in attempt to
improve cell viability. It was observed that cell death was occurring prior to puromycin
selection. Bacterial contamination was suspected given that both the untransduced control
cells, and positive controls containing a GFP control lentivirus generated within out lab,
showed no evidence of contamination and the source was traced to the viral stocks. To
confirm, all components/reagents used for transductions, including fresh vials of virus, were
inoculated into medium and incubated at 37oC for 72-96 hours. Bacterial outgrowth was
detected only where viral media was inoculated, confirming contamination of viral stocks
purchased from a commercial source.

Subsequently, we generated our own lenti-reporter virus containing DACH1-3’UTRLuciferase-plasmid purchased from ABM. Inc. (the same supplier of the original viruses).
Our lentivirus successfully transduced DAOY cells and generated puromycin resistant
colonies. However, transduction of semi-adherent medulloblastoma cell lines was
unsuccessful. The reasons for this were unclear, and further experiments were abandoned due
to time constraints. Possible explanations include a low viral MOI, not sufficient for
transducing cells; the slower proliferation rates of the semi-adherent cell lines, or the
tendency for these cells to aggregate reducing surface area available for viral transduction.
For future investigation/experiments, an alternative optimised protocol is required.

7.3

Transient transfection to alter miR-200b levels

In the meantime, an alternative approach was used to investigate whether restoring miR-200b
expression had any effect on DACH1 mRNA/protein expression. Cells with low levels of
miR-200b expression were transiently transfected with a single hsa-miR-200b-3p mimic to
restore miR-200b levels, followed by analysis of DACH1 mRNA and protein expression.
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Two concentrations (20nM and 50nM) of hsa-miR-200b-3p mimic (miR-200b mimic) and
miRNA negative control#1 (control) were selected, and post-transfection analysis was
performed 24 and 48 hours post-transfection. Transfection efficiency was confirmed based on
an increase in detectable mir-200b mimic compared to cells transfected with the control.
Although transfection of mir-200bmimic successfully increased miR-200b to detectable
levels, post-transfection analysis of DACH1 mRNA did not reveal any noticeable difference
in expression at either time point. However, given that translation repression may occur even
when mRNA remains stable (Djuranovic, Nahvi, & Green, 2012; Selbach, Schwanhausser, &
Thierfelder, 2008), DACH1 protein was assessed by western blot, to determine if translation
repression was evident. At both 24 and 48 hours post transfection, with 20nM of
mimic/control, no decrease in DACH1 protein was detected. Using 50nM of mimic, there
was some indication of protein repression in mimic-transfected cells compared to untransfected cells, as determined by visual analysis. Unfortunately, no repeat experiment was
performed for confirmation due to time constraints.

Others have demonstrated successful inhibition of target following transfection of miR-200b
mimics (Hailin et al., 2013; Ye et al., 2014), however we were unable to show downregulation of DACH1 following transfection with a mir-200b mimic. This is suggestive that
miR-200b is not capable of regulating DACH1 expression, however it would be premature to
make this assumption without additional experiments.

Reporter screening would be ideal, and would provide a more conclusive indication of any
potential interaction (Thomson, Bracken, & Goodall, 2011). Such experiments would
involve the development of reporter cell lines, and assessing reporter activity relative to the
amount of miR-200b expressed. Subsequently assessing reporter expression after transfection
of mir-200b mimics and antagomirs would provide evidence of miR-200b directly interacting
with the putative target within the DACH1 3’UTR. Furthermore, generating lentiviruses with
mutations to the putative binding site, and assessing changes in reporter expression, in a
similar fashion as described above, would provide direct evidence of whether miR-200b
targets the DACH1 3’UTR directly. Evidence of miR-200b binding to the DACH1 3’UTR
could then be confirmed by transfection of mimics and assessment by qRT-PCR and western
blot, similar to what is described here.
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In addition, regarding experimental design, which involved only two time points (24 and 48
hours), it is possible that any detectable changes occurred outside of this range. A broader
range, with earlier time points (6-12 hours) and later time points (72 hours), would allow a
more comprehensive assessment of any potential changes in DACH1 expression. In the longterm, this could be enhanced by the use of a lentiviral vector to stably maintain up regulation
of miR-200b. Similarly, the amount of mimic used may need to be adjusted for any effects to
be observed.

It is also acknowledged that assessing only one microRNA, miR-200b, may be a limited
approach. It is likely that the regulation of DACH1 is more complex, involving additional
miRNAs, particularly those of the miR-200 family sharing the same seed sequence (miR200c, and miR429). Including additional members of the miR-200 family, both individually
and in combination, would be an ideal approach.

Another possibility is that there may be alterations within the 3’UTR that abrogate miR-200b
binding. Although this was not investigated here, it has been previously demonstrated that
during oncogenic transformation, a gene’s 3’UTR may become truncated or elongated,
enabling a gene to escape miRNA regulation (L. Li et al., 2014; Lianoglou, Garg, Yang,
Leslie, & Mayr, 2013). As the mRNA sequence of DACH1 in our cell lines was not
examined, this would be an interesting concept for further investigation.

7.4

TaqMan qRT-PCR assays

The small nucleolar-RNAs (snoRNAs); RNU44 and RNU48, which were selected as internal
controls, are commonly used for assessing miRNA expression, however do show variation in
expression in different cancer types (Gee et al., 2011). In this study, some discrepancies in
the efficiency of the RNU44 and RNU48 primers were observed, and this introduces some
bias. Notably different Ct values for RNU44 were detected between D425 and the other cell
lines. Subsequently, RNU48 was assessed as a control to be used in D425, and demonstrated
similar efficiency to RNU44.
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In subsequent post-transfection experiments, variation in RNU44/RNU48 expression was
observed across all samples, which hints at a change induced by the transfection process or
by miR-200b. Such variation was not expected when these internal control were selected, as
previous analysis has demonstrated their validity (Genovesi, Anderson, Carter, Giles, &
Dallas, 2012). Additionally, experimental error may be a factor, due to inexperience with the
technique, or potentially the transfections themselves affect RNU44/RNU48 expression.
Taking these possibilities into consideration, a range of potential internal controls should be
assessed to reduce this variation.

Considering the consistent variation in internal control expression between cells that were
transfected with mir-200b compared to those transfected the control, data was simply
presented as 2-ΔCt (i.e. expression respective to control) and Log2 transformed, to avoid
potential bias.

7.5 Additional considerations
Although here it is proposed that DACH1 and miR-200b may be involved in Group 4
medulloblastoma pathogenesis, we were only able to test this association in Group 3
medulloblastoma cell lines. However, DACH1 up-regulation was detected in all
medulloblastoma subgroups relative to normal cerebellum, suggesting that DACH1
overexpression may be relevant to medulloblastoma more generally. Taking this into
consideration, it is possible that any association between DACH1 and miR-200b in
medulloblastoma pathogenesis is not exclusive to Group 4. Indeed, we observed the inverse
correlation in most of the cell lines including those of the SHH subgroup. Additionally, the
roles of DACH1 and miR-200b in EMT raise the possibility that this putative association is
relevant across all metastatic medulloblastoma, not just in Group 4.
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8.0

CONCLUSION

The regulation of DACH1 by miR-200b remains to be definitively demonstrated. Although
our findings were not suggestive of regulation at either the mRNA or protein level, initial
correlative evidence would suggest an association. Additionally, our approach to assessing
the functional relationship between DACH1 and miR-200b was limited due to both time
constraints and issues with contaminated lentivirus requiring an alternative experimental
approach. Considering all possibilities addressed above, the regulation of DACH1 is likely to
be more complex, and probably involves additional microRNAs, particularly those of the
miR-200 family with identical seed sequences to miR-200b (mir-200c and miR-429). If miR200b does target DACH1, it may only produce a subtle change.

Cell lines stably transduced to express miR-200b could be used for long-term assessment of
the effects of miR-200b not only on DACH1, but also the effects on cell phenotype, and
particularly cell migration. Finally, although ambitious at this point, the development of
mouse models engineered to over-express DACH1 and/or under-express miR-200b could
potentially provide valuable understanding into the mechanisms of medulloblastoma
pathogenesis.

Finally, although the role of DACH1 as an oncogene in medulloblastoma, remains to be
conclusively demonstrated, the available data suggest that further characterisation of the role
of DACH1 in medulloblastoma pathogenesis is warranted.
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Appendix B. qRT-PCR data

Cycle Threshold
Standard Deviation
ΔCt
ΔΔCt
Relative Quantitation

Abbreviations
Ct
SD
Normalised expression (Average Ct target – Average Ct internal control
Relative expression (ΔCt test – ΔCt control)
RQ

qRT-PCR analysis of miR-200b in medulloblastoma cell lines
1

1

2

2

Daoy
miR-200b 29.33775 28.23541 27.96166
27.03735 26.04543 25.43368
RNU44

30.9249
28.95017

30.3264
28.47356

32.2878 30.77175
24.04086 23.79317

32.1551
25.61797

31.09239
24.38796

29.41409 29.85187
24.00339 24.49192

UW228
miR-200b
RNU44
PER547
miR-200b
RNU44
D283
miR-200b
RNU44
D341
miR-200b
RNU44
D425

1

35 32.94062 32.02717
25.649 24.34473 23.63739

2

3

3

33.23739
33.91859 33.03051 30.31595 36.436893 35.600822 30.62758
34.47557
22.26352 21.78283 20.87944
22.123
22.156 20.60696 24.46166 23.82999

3 Average Ct SD
30.59115
23.70048

32.23739
23.6449

Ct SD

30.054603 1.3612675 2.3718901
25.934338 1.9423731

ΔCt

ΔΔCt

2^-ΔΔCt

Log2 RQ

4.120265

-6.409015 84.977886 6.4090156

31.783034 1.7608922 1.8990813 7.1926971
24.590337 0.7111738

-3.336583 10.102101 3.3365834

33.28951 1.7537825 2.1293431 10.873032 0.3437517 0.7879895
22.416478 1.243004

30.94545 30.12548 29.63841
25.96366 24.92622 23.86636

34.11824
21.62347

34.42992 33.86202 34.3392 33.8964 33.373714
20.97276 20.27967 21.67582 20.66049 19.996859

32.747648 1.8253176
22.218368 2.0384087

1

0

32.149 31.39827 30.14953
24.77855 23.96069 22.82445

33.91484
21.66571

33.7179 33.73136 34.83827 33.5502
20.61304 20.42971 21.72953 21.89726

33.328549 1.075924 1.7216024 10.832944 0.3036637 0.8101923
22.495604 1.3439874

-0.303663

36.90059

36.55563
31.45496
22.39714 22.72757

33.269867 1.3609153 1.7390875
23.602202 1.0827442

miR-200b 32.95625 31.9533 33.25469
24.50856 24.71615 24.80508
RNU48

22.45871

2.736219 10.529281

9.667665

0

-0.343751

-0.861615

1.817072 0.8616156

qRT-PCR analysis of miR-200b expression in cell lines, 24 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to RNU44/RNU48
1

1

1

2

2

2 Average

SD

Ct SD

ΔCt

2^-ΔCt

Log2 RQ

-1.0367 2.05151

1.03668

34.5461 33.86804 33.628817 0.68854 1.74598 9.33364 0.00155

-9.3336

D341 mimic
200b

21.52807 21.48088 21.3638 24.9736 24.36937 24.28898 23.000792 1.55902 1.90097

RNU44

25.27176 25.13319 24.9591 22.9666 22.92638 22.96787 24.037475 1.08772

D341 control
200b

33.31676 32.99001 32.6836 34.3684

RNU44

25.85066 25.87212 25.9705 22.8274

22.649 22.60136 24.295182 1.60448

D425 mimic
200b

22.76947 22.83269 22.8315 23.6105 23.57149 23.47665 23.182048 0.34584

RNU48

24.97602 24.97247 24.9687 25.5533 25.59148 25.58709 25.274838

0.4596

-2.0928 4.26572

2.09279

33.385556 1.41623 1.41769 8.37001 0.00302

-8.37

0.3027

D425 control
200b
RNU48

32.67465 31.51094 32.6603 35.0083 35.07362
24.9633 25.08756 24.9324 25.0912 25.00321 24.99139

25.01555 0.06435

PER547 mimic
200b

21.57425 21.50414 21.4114 23.2451 23.20869 23.04483 22.331403

0.8384 1.68396

-1.6292 3.09342

1.6292

RNU44

25.53641 25.45538 25.2642 22.4639 22.52344 22.52037 23.960605 1.46041
36.95118 36.41425 36.6832 36.9732 35.55816 35.30413 36.314012 0.65549 0.99237 11.6624 0.00031

-11.662

PER547
200b
RNU44

25.4038 25.36094 25.4203 24.0012 23.86684 23.85657 24.651612 0.74507

D283 mimic
200b

22.22203 22.17984 22.1515 23.0709 23.03091 22.90829 22.531016 0.42525 1.34479

-1.844 3.59014

1.84404

RNU44

25.41844 25.40425 25.4272 22.8376 22.78781

32.9179 33.74686 33.7841 35.1563 35.45034 34.59473 34.275028 0.87768 1.52129 9.28157 0.00161

-9.2816

24.375056 1.27578

D283 control
200b
RNU44

26.26553

26.256 26.1745 23.9212 23.75376 23.58982

24.99346 1.24257

qRT-PCR analysis of miR-200b expression in cell lines, 48 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to RNU44/RNU48
1

1

1

2

2

2 Average

SD

Ct SD

ΔCt

2^-ΔCt

Log2 RQ

D341 mimic
200b

24.552967 23.854042 23.599588 24.972551 24.921453 24.914639 24.46920667 0.547413953

RNU44

21.538748 21.803959 21.522717 21.888258 21.977558 21.849342 21.76343033 0.172665887

0.574 2.705776333 0.153278119 -2.705776333

D341 control
200b

34.174767 36.919975

RNU44

22.542562

33.07282 34.115894 33.657753 33.456047
22.510897

23.98059 23.759356 23.862974

33.6954562 0.413018382 0.779176

10.3641804 0.000758701

-10.3641804

23.3312758 0.660704987

D425 mimic
200b

26.116674 26.044378 26.088703 24.615269 24.326649 24.432652 25.27072083 0.817162275 0.827505

RNU48

25.216892 25.094225 25.117048 24.979593 24.903418

0.2459315 0.843271148 -0.074032758

24.83756 25.02478933 0.130425547

D425 control
200b

34.248333 34.372295

34.1505

33.76569

34.66682 33.299202 34.08380667 0.441861531 0.493221 9.328851833 0.001555019 -9.328851833

RNU48

24.608341 24.972895 24.366798 24.999498 24.735964 24.846233 24.75495483 0.219147201

PER547 mimic
200b

21.938042 22.042686 22.033072 25.474108

RNU44

22.827246 21.958355 21.736357

25.3925

23.3760816 1.680311545 1.720426

22.10297 22.286386 21.860746

1.1938188 0.437144211

-1.1938188

22.1822628 0.369350512

PER547 control
200b

36.95305 37.725636

36.3772

35.42836

34.3852

35.96322 36.13877767 1.068375121 2.170457 12.18951917 0.000214086 -12.18951917

22.153275 22.079008 21.961515 25.992462 25.910704 25.598587

23.9492585 1.889301078

200b

25.095387

25.5407185 0.258051448 0.456851 1.740204833 0.299327175 -1.740204833

RNU44

23.887083 24.141254 24.051447

22.99429 23.801323 23.927685 23.80051367 0.376991504

36.616478

33.53491 32.781097 32.351334

RNU44
D283 mimic

25.30452 25.715897 25.835491 25.698816

25.5942

D283 control
200b
RNU44

0 36.453217

22.72779 23.953176 22.627365 24.514252 24.520742 24.495136

34.3474072 2.042113168 2.230966
23.777057 0.898322239

10.5703502 0.000657669

-10.5703502

qRT-PCR analysis of miR-200b expression in cell lines, 24 hours post-transfection with 50nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to RNU44/RNU48
1
D341 mimic
200b
RNU44
D341 control
200b
RNU44
D425 mimic
200b
RNU48
D425 control
200b
RNU48
PER547 mimic
200b
RNU44
PER547 control
200b
RNU44
D283 mimic
200b
RNU44
D283 control
200b
RNU44

1

1

2

2

2 Average

SD

Ct SD

21.0093 21.00304 24.07897 21.83594667 1.045000335 1.540448
23.4757 23.43556 23.36767 22.29775667 1.131792751

ΔCt

2^-ΔCt

21.70596
21.30863

21.71921 21.4992
21.16586 21.03312

31.64931
24.47125

31.72205 31.58662 31.64931 31.72205 31.58662
24.3222 24.33059 24.47125 24.3222 24.33059

0.00644332

-7.27798

25.96286
25.83469

25.49348 25.42987 22.06564 21.67721 31.76428
25.286096 3.311787449 3.339333 -0.093160667 1.066704568
25.7955 25.78981 24.95746 24.98006 24.91802 25.37925667 0.428026818

0.093160667

32.17822
24.97568

31.98237
24.87556

31.8603 32.00696333 0.130950132 0.138942
24.9724 24.94121333 0.046443225

7.06575 0.007464441

-7.06575

21.48369
22.37408

21.45464 21.48848 21.64073 21.45058 21.31722 21.47255667 0.094510347 0.537933
22.26259 22.3184 23.46352 23.40174 23.23471 22.84250667 0.529565485

-1.36995 2.584616084

1.36995

32.83283
24.96535

32.98308 33.08717 32.83283 32.98308 33.08717 32.96769333 0.104402334 0.125423
24.85565 24.79774 24.96535 24.85565 24.79774 24.87291333 0.06950681

8.09478 0.003657871

-8.09478

31.8603 32.17822 31.98237
24.9724 24.97568 24.87556

31.65266 0.055339787 0.087961
24.37468 0.068371152

22.76589 22.880306 22.77436 21.13978 20.98208 21.03628 21.92978267 0.879059396 0.891459
23.01532 23.09686 23.04672 22.93132 22.75279 22.70247 22.92424667 0.148167553
32.44007
23.73654

32.6546 32.32044 32.44007 32.6546 32.32044 32.47170333 0.138241883 0.147225
23.68784 23.61339 23.73654 23.68784 23.61339 23.67925667 0.050640799

-0.46181 1.377268651

Log2 RQ

7.27798

-0.994464

1.99234018

0.46181

0.994464

8.792446667 0.002255329 -8.792446667

qRT-PCR analysis of DACH1 expression in cell lines, Log2 normalised to GAPDH, relative to D283
1

2

32.94137 33.04392 33.36116 33.56143

35

35

32.31932 32.52079

33.468499

16.819

16.853

14.55992 14.75795

14.80079

27.8913 28.35166 28.48279 22.28466

27.26823 27.03695 29.44535 28.09034

27.395187

1.9260906 2.4187078 10.980673 2.1928111 0.2187248

GAPDH 14.57776 14.75679 14.78471 15.13801 17.35307

17.8131 17.76897 18.27613 17.26208

16.414513

1.4629841

21.38265 21.66921 19.97557

21.959348

0.9464508 1.4715609 5.1282463

18.41454 18.11345

16.831101

1.1268196

24.94711 24.89661 25.77412 24.47594

26.208769

1.3758596 1.7212747 8.7878622

GAPDH 16.45743 16.48814 16.53477 16.64414 18.21558

18.29747 18.98769

17.420907

1.0343099

D341
DACH1

22.20039

23.537975

1.1665269 1.2683836 6.9259158

16.5373 16.69411 17.32265 17.097525

16.612059

0.4980081

UW228
DACH1

27.7054

13.979 14.14775

2

3

3 Average Ct Standard Deviation Ct SD

ΔΔCt

2

GAPDH 13.49108 13.79862

1

ΔCt

1

Daoy
DACH1

1

2^-ΔΔCt

Log2 RQ

0.960992 1.5634146 18.667709 9.8798465 0.0010614

-9.879846

1.2331908
-2.192811

PER547
DACH1

22.71583 22.69571 22.78952 22.88313 21.56316

GAPDH 15.87293 15.81801 15.89992 15.96786
D283
DACH1

27.27899 27.72077 27.85543 27.92399 25.00596

23.22119 23.27677 23.29145 23.23901 25.99904

GAPDH 15.93585 16.08492
D425
DACH1

18.2921

23.57904 23.52437 23.02143 23.00439 25.05538

GAPDH 15.46338

15.1391

14.7202

14.6054 18.25849

16.27

18.7073 16.45564

24.94749

23.85535

17.19458

15.896858

0.8404654 1.5976112 7.9584917
1.3586682

-3.659616 12.637297

0

1

3.659616

0

-1.861946 3.6349774 1.8619464

-0.829370 1.7769099 0.8293706

qRT-PCR analysis of DACH1 expression in cell lines, 24 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to GAPDH
1

2

2

2 Average

1

1

DACH1

23.91269

23.88669

GAPDH

18.77639 18..81374 18.85933 17.68149 17.83187 17.95116

SD

Ct SD

ΔCt

2^ΔCt

Log2 RQ

D341 mimic
23.8998 24.35321

24.4582 24.71346 24.2040083
18.220048

0.3226235

0.591888 5.98396033 63.29239841 5.983960333

0.4962309

D425mimic
DACH1

28.29979

28.23658 28.35454 27.10415 27.33318 27.45576 27.7973333 0.51128814

GAPDH

19.59138

19.55558 19.09992 17.73256 17.83134 17.98763 18.6330683 0.80183266

DACH1

23.73677

23.70025 23.74679 23.78208 23.87966 23.93569 23.7968733 0.08346592

GAPDH

18.35739

18.32396 18.35612

18.0478 17.99704

17.9779 18.1767017 0.17075337

DACH1

27.80856

27.76054 27.87219

27.3417 27.54622

27.665842 0.19559811

GAPDH

18.5109

0.880431

9.164265 573.7446557

9.164265

PER547 mimic
0.175963 5.62017167 49.18585809 5.620171667

D283 mimic
18.55209 18.46779 17.34076 17.35401

17.3701

18.04511 0.57032895

0.602938

9.620732 787.2794443

9.620732

1.558344

7.015495 129.3821696

7.015495

D341 control
DACH1

23.13936

23.17296 23.19764 26.62645 26.53385 26.42056

24.84847 1.67962377

GAPDH

17.75568

17.98409 17.99052 17.75189 17.73875 17.77692

17.832975 0.10971628

DACH1

27.90295

27.94307

GAPDH

19.05323

D425 control
27.7853 26.47859 26.44867 26.58408 27.1904433 0.68951752

19.1196 19.09992 17.66661 17.71298 17.80364

0.898571 8.78111333 439.9248642 8.781113333

18.40933 0.68305709

PER547
DACH1

22.9135

22.91904

22.9501 23.61335 23.67364 23.62402

23.282275

0.3553969 0.7277777 5.54459167 46.67543836 5.544591667

GAPDH

18.46054

18.40936 18.44321 17.07402 16.96351 17.07546 17.7376833

0.7011624

DACH1

27.55064

27.59835

0.1291298

GAPDH

18.58314

D283 control
27.561 27.86538 27.86538 27.93596
18.60515 18.60237 17.68924 25.94112 17.78027

27.702266

18.252034 0.39311391

0.454163

9.450232 699.5250931

9.450232

qRT-PCR analysis of DACH1 expression in cell lines, 48 hours post-transfection with 20nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to GAPDH
1

1

1

2

2

2 Average

SD

Ct SD

ΔCt

2^ΔCt

Log2 RQ

D341 mimic
DACH1

23.299927 23.431452 23.508732

24.93911 24.966257 24.952692 24.18302833 0.772107428

GAPDH

18.943432 18.579432 18.484972 20.317513 20.274754 20.205818

19.4676535

23.952806 23.958572 24.042336 23.884453 23.878902 23.847736

23.9274675 0.065025981

1.119886 4.71537483 26.27055607 4.715374833

0.81116868

D341 control
DACH1
GAPDH

0.132252 4.89886767 29.83363091 4.898867667

19.24158 18.916302 18.899393 19.045921 19.081867 18.986536 19.02859983 0.115161148

D425mimic
DACH1

26.06653

GAPDH

18.508165

26.27913 26.442982

27.98095 27.969145 27.992262 27.12183317 27.12183317

1.111041 7.89874633 238.6489756 7.898746333

18.52896 18.544676 19.878576 19.944468 19.933676 19.22308683 19.22308683

D425 control
DACH1

25.4806 25.741081 25.930473 27.702425 27.660604 27.638617

26.6923 0.983776386 -1.153707

GAPDH

18.817703 18.719215 18.566668 19.944006 19.958818 19.772158

19.296428 0.602679979

22.879507 22.907139 22.927818 22.686193 22.721674 22.697565

22.803316

7.395872 168.4144363

7.395872

PER547 mimic
DACH1
GAPDH

17.54823

17.87284 17.635185

22.803316

0.541169 4.62042033 24.59716831 4.620420333

18.55324 18.996838 18.491041 18.18289567 18.18289567

PER547 control
DACH1

22.501484 22.606667 22.935978

GAPDH

17.891216

23.2088 23.197466 23.114368

22.9274605 0.280305278

0.555234 4.64546233 25.02784785 4.645462333

17.81557 17.711107 18.742556 18.796707 18.734833 18.28199817 0.479284319

D283 mimic
DACH1

26.19131 26.163534 26.210775 27.599478 27.612772 27.557426 26.88921583 0.701008718

GAPDH

18.35787

18.43601 18.344559

19.11062 19.031214

18.96977

0.775911 8.18087533 290.1942922 8.180875333

18.7083405 0.332603851

D283 control
DACH1

26.738604

26.66084 26.774017 27.350254 27.338509

GAPDH

18.409344 18.323383 18.221207

27.33284 27.03251067 0.309874357
18.317978 0.076901639

0.319274 8.71453267 420.0836037 8.714532667

qRT-PCR analysis of DACH1 expression in cell lines, 24 hours post-transfection with 50nM has-miR-200b-3p mimic/mRNA negative control #1, Log2 normalised to GAPDH
1

1

1

2

2

2 Average

SD

Ct SD

ΔCt

2^ΔCt

Log2 RQ

D341 mimic
DACH1

23.17405 23.12604 22.91455 23.75813 23.58543

23.6579

23.36935 0.312326337 1.032196333 5.409946667 42.51637428 5.409946667

GAPDH

17.06121 16.82255 17.05308 18.94008 18.97713 18.90237 17.95940333 0.983809702

D341 control
DACH1

25.29235 25.63156 25.59295 25.29235 25.63156 25.59295

25.50562 0.151626191 0.155278891 6.102083333 68.69262606 6.102083333

GAPDH

19.44129 19.40941 19.35991 19.44129 19.40941 19.35991 19.40353667 0.033481817

D425mimic
DACH1

27.1276 27.08355 27.03174 28.37879

28.3133 28.36819
19.6568

19.351565

DACH1

28.78645 28.58378 28.47351 28.78645 28.58378 28.47351

28.61458

GAPDH

19.51728

GAPDH

19.07971 19.09004 18.97393 19.72562 19.58329

27.717195 0.637157805 0.707991419

8.36563 329.8417019

8.36563

0.30867747

D425 control
19.3758 19.32172 19.51728

0.12960026 0.153605192 9.209646667 592.0793251 9.209646667

19.3758 19.32172 19.40493333 0.082451973

PER547 mimic
DACH1

24.11801 24.12504

23.8416 23.21038 23.19758 23.17419 23.61113333 0.427529331

GAPDH

18.67534 18.63002 18.39411 19.14321 19.14737 19.04628 18.83938833 0.288381756

0.51569891

4.771745 27.31733803

4.771745

PER547 control
DACH1

25.51031 25.60321 25.27715 25.51031 25.60321 25.27715 25.46355667 0.137157298 0.156392311 5.149146667

GAPDH

20.36198 20.37292 20.20833 20.36198 20.37292 20.20833

35.4852279 5.149146667

20.31441 0.075142734

D283 mimic
DACH1

28.02566 27.97278 27.91611 27.92245 28.01564 27.60113 27.90896167 0.143796683 0.383694633 9.079776667

GAPDH

18.50107 18.52217 18.41807 19.29328 19.16208 19.07844

541.109465 9.079776667

18.829185 0.355730355

D283 control
DACH1

29.96095 29.90553 29.79715 29.96095 29.90553 29.79715 29.88787667 0.068026172 0.076160602 9.954003333 991.8673175 9.954003333

GAPDH

19.96734 19.88682 19.94746 19.96734 19.88682 19.94746 19.93387333 0.034247294

